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 Salivary gland mucoepidermoid carcinoma is rare but causes significant 
morbidity in patients who are diagnosed. Slow, persistent growth as well as resistance 
to chemotherapy treatment has greatly hindered the response of these tumors to 
conventional therapies. Emerging research has identified a population of highly 
tumorigenic cells, termed cancer stem cells, which possess stem cell-like properties of 
multipotency, self-renewal, and unique tumorigenic potential compared to non-cancer 
stem cells. Importantly, cancer stem cells have been shown to be resistant to 
chemotherapy and radiation therapies. Selective targeting of stem cell associated 
pathways could prevent therapy resistance.  
Here, we investigated the presence of cancer stem cell markers ALDH, CD44, 
CD24, and CD10 and the tumorigenic potential of human mucoepidermoid carcinoma 
(HMC) cells sorted for these stem cell markers in in-vitro salisphere formation and in-
vivo xenograft growth models. FACS-sorted ALDHhighCD44high cells preferentially 
formed salispheres in primary and secondary ultra-low attachment, serum-free culture 
compared to ALDHlowCD44low cells suggesting that ALDHhighCD44high cells are capable 
of self-renewal. Importantly, ALDHhighCD44high sorted cells consistently formed primary 
and secondary tumors compared to ALDHlowCD44low cells when implanted in-vivo, each 
tumor replicating the original ALDH/CD44 sub-populations suggesting that 
ALDHhighCD44high cells are capable of tumorigenicity and multipotency. Together, these
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results suggest that ALDHhighCD44high cells identify a population of uniquely tumorigenic 
cancer stem cells.  
In an effort to identify a therapeutic to target the ALDHhighCD44high cells, we used 
the MDM2/p53 small molecule inhibitor, MI-773, and treated human mucoepidermoid 
carcinoma cells using low doses of the drug. We found a significant reduction of 
ALDHhighCD44high cells in-vitro as well as in-vivo. Importantly, we also noted an increase 
in p21 expression and decrease in Bmi-1 expression suggesting that accumulation of 
p53 in the cell by inhibiting MDM2 greatly affects self-renewal and differentiation 
associated protein. Treatment of human mucoepidermoid carcinoma cells with MI-773 
also induced apoptosis and cell-cycle arrest both in-vitro and in-vivo. Together, these 
results demonstrate the presence of highly tumorigenic cancer stem cells in salivary 
gland mucoepidermoid carcinoma. Further, we propose the use of MDM2 inhibitors in 
the selective ablation of cancer stem cells as a therapeutic target for the treatment of 







Salivary gland cancer is rare, accounting for approximately 2-6.5% of all head 
and neck cancers, with 3,300 new cases each year (1-3). The most common form of 
salivary gland cancer, mucoepidermoid carcinoma (MEC), represents about 30-35% of 
all malignant salivary gland tumors (3-10). Treatment of mucoepidermoid carcinomas 
consists of surgical resection, radiation treatment, and neck dissection. While effective 
for lower grade tumors, conventional treatments for high-grade or recurrent tumors are 
often ineffective leading to significant facial disfigurement and morbidity. Importantly, 
mucoepidermoid carcinomas are resistant to conventional chemotherapy, thereby 
limiting treatment options for patients with advanced disease.  
Increased understanding of the pathobiology of mucoepidermoid carcinomas has 
been limited by the lack of cell line and xenograft models. Previous work published in 
our laboratory by Warner and colleagues unveiled the generation of stable human 
mucoepidermoid carcinoma (HMC) cells lines capable of forming tumors in 
immunodeficient (SCID) mice (11). One of the three cell lines, UM-HMC-1, was 
generated from a stage IVa, intermediate grade tumor taken from the minor salivary 
gland of the buccal mucosa of the patient. The other two cell lines, UM-HMC-3A and 
UM-HMC-3B, were generated from a patient with a stage IVb, intermediate grade 
tumor. The UM-HMC-3A cells were generated from a recurrent tumor found in the left 
hard palate while the UM-HMC-3B cells were generated from the lymph node
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metastasis in the same patient. Importantly, all three cells lines have been genotyped as 
well as passaged up to 100 times in-vitro and are capable of forming tumors in-vivo. 
With appropriate models and resources to begin research on salivary gland 
mucoepidermoid carcinomas, we first sought to learn how mucoepidermoid carcinoma 
tumors are generated and maintained as well as identify targetable pathways 
associated with cancer aggressiveness.  
Emerging research has identified the presence of a population of cells termed, 
cancer stem cells, that display stem cell-like properties. Interestingly, cancer stem cells 
display unique tumorigenicity as well as an ability to self-renew and differentiate into 
non-cancer stem cells (further elaboration of salivary gland cancers and the properties 
of cancer stem cells is provided in Chapter II). Cancer stem cells are frequently isolated 
using FACS sorting for surface or enzymatic markers such as ALDH, CD44, and CD24. 
Importantly, studies have shown that cancer stem cells defined by these specific marker 
combinations are resistant to conventional chemotherapy and radiation treatments due 
to slower proliferation rates and expression of transporter proteins (12-18). Survival of 
cancer stem cells following treatment allows for reconstitution and recurrence of the 
tumor leading to disease relapse and patient morbidity. While the identification and 
isolation of cancer stem cells have been found to be critical in correctly treating many 
cancer types, cancer stem cells have not been identified or isolated in salivary gland 
mucoepidermoid carcinomas. 
Due to the resistance of cancer stem cells (CSCs) to conventional treatment, 
much research has been dedicated to the identification of cancer stem cell-targeted 
therapies with the hypothesis that combined chemotherapy and CSC-targeted therapies 
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will eliminate all cells from the tumor and prevent tumor recurrence and disease relapse. 
Drugs targeting the Notch, Wnt, Hedgehog, IL-6, and PI3K/AKT pathways have been 
investigated for therapeutic effectiveness against cancer stem cells in several different 
cancer types, however, the efficiency of these drugs is often limiting by the lack of 
specificity towards the targeted pathway (19-22). One pathway that has yet to be 
investigated in the context of cancer stem cell function is that of the tumor suppressor 
protein, p53. While much research has focused on the role of p53 in cell cycle 
regulation and the induction of apoptosis, research in induced-pluripotent stem (iPS) 
cells also identified p53 as a key player in embryonic stem cell function. Several studies 
reported that by knock down or reducing the levels of p53 within the cell that the 
efficiency of reprogramming differentiated cells to iPS cells was greatly enhanced (23-
27). In the context of cancer, researchers also found that elimination of p53 leads to the 
expansion of malignant progenitor cells and the development of mixed lineage tumors 
(28).  
p53 is predominately regulated by mouse double minute 2 (MDM2) which 
functions as a E3 ubiquitin ligase marking p53 for degradation, can also bind p53 
blocking its transactivation domain. MDM2 is frequently overexpressed in cancer and 
serves as an oncogene in many cancers due to its function in inhibiting p53. Ideally, 
inhibition of MDM2 binding to p53 in the cancer cell would prevent the blockage and 
degradation of p53 thereby releasing it into the cell to induce cell cycle arrest and 
apoptosis. Many small molecule inhibitors have been developed to interrupt MDM2/p53 
binding, however, lack of specificity or ineffective clinical translatability are significant 
challenges to targeting this interaction (29-33). MI-773, developed in Dr. Shaomeng 
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Wang’s laboratory at the University of Michigan, shows enhanced binding specificity 
when compared to the p53 and MDM2 inhibitor gold standard, Nutlin-3a (34). In several 
cancer types, MI-773 was effective in inducing apoptosis and drastically reducing tumor 
volume. Importantly, MI-773 was effective in cell with both wild-type and mutant p53 
(35). As p53 plays an important role in stem cell biology, the potential role of p53 
activation as a consequence of MDM2 inhibition in the ablation of cancer stem cells is 
an intriguing question. Considering salivary gland cancers frequently contain wild-type 
p53, MDM2 inhibition is an interesting therapeutic to study in this cancer type (36-40). 
However, no research has been done studying MDM2 inhibitors in the context of 
salivary gland cancer or more specifically, in the context of salivary gland cancer stem 
cell biology. 
The central hypothesis of this work is that a subpopulation of highly tumorigenic 
cancer stem cells defines the pathobiology of salivary gland mucoepidermoid 
carcinomas. To address our hypothesis, this project seeks to both define the role of 
cancer stem cell in the initiation of mucoepidermoid carcinoma and to determine the 
therapeutic efficacy of MDM2 inhibition via MI-773 on cancer stem cell function in 
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Salivary Gland Cancer Stem Cells 
Abstract 
Emerging evidence suggests the existence of a tumorigenic population of cancer 
cells that demonstrate stem cell-like properties such as self-renewal and multipotency. 
These cells, termed cancer stem cells (CSC), are able to both initiate and maintain 
tumor formation and progression. Studies have shown that CSC are resistant to 
traditional chemotherapy treatments preventing complete eradication of the tumor cell 
population. Following treatment, CSC are able to re-initiate tumor growth leading to 
patient relapse. Salivary gland cancers are relatively rare but constitute a highly 
significant public health issue due to the lack of effective treatments. In particular, 
patients with mucoepidermoid carcinoma or adenoid cystic carcinoma, the two most 
common salivary malignancies, have poor long-term survival rates due to the lack of 
response to current therapies. Considering the role of CSC in resistance to therapy in 
other tumor types, it is possible that this unique sub-population of cells is involved in 
resistance of salivary gland tumors to treatment. Characterization of CSC can lead to 
better understanding of the pathobiology of salivary gland malignancies as well as to the 
development of more effective therapies. Here, we make a brief overview of the state-
of-the-science in salivary gland cancer, and discuss possible implications of the cancer 




 Salivary gland cancer is a relatively rare yet deadly disease. On average, 3,300 
new cases are diagnosed every year in the USA. Due to limited mechanistic 
understanding of the disease and lack of effective regimens for chemotherapy, surgery 
is still the main treatment option of these patients. As a consequence, treatment for 
these tumor is generally accompanied by significant morbidity and debilitating facial 
disfigurement. Malignant tumors are generally fatal. This is reflected in the 5-year 
survival rate that drops drastically from 78% for stage I tumors to 25%, 21%, and 23% 
for stages II-IV, respectively (1). Of much concern is the fact that the survival of patients 
has not improved over the last 3 decades, which is in contrast with the significant 
improvement in survival observed in other glandular tumors. Such data suggest that 
focused research efforts on the understanding of the pathobiology of these tumors could 
lead to significant improvements in patient survival and quality of life. 
 Mounting evidence supports the existence of a sub-population of tumorigenic 
cells that possess stem cell-like characteristics in many tumor types (e.g. breast cancer, 
pancreatic cancer, head and neck squamous cell carcinomas). These cells, termed 
cancer stem cells (CSC), are capable of self-renewal and also to differentiate into cells 
that constitute the bulk of the tumor. Cancer stem cells are resilient cells that play a 
major role in resistance to chemotherapy and radiation therapy in other cancer types (2-
4). While such studies are unveiling the mechanisms of resistance to therapy in other 
malignancies, very little is known about the resistance of salivary gland tumors. Indeed, 
one of the most pressing clinical issues in salivary gland cancer is the poor response to 
therapy (5). It is certainly possible that low proliferation rates contribute to resistance to 
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therapy in a group of salivary gland tumors but another possibility is that cancer stem 
cells play a role in the resistance to therapy observed in these tumors. Characterization 
of stem cells in these tumors might lead to the identification of novel pathways that 
could be targeted to sensitize these tumors to chemotherapy. 
Salivary Gland Structure and Function 
Salivary glands play an essential role in protection and maintenance of health in 
the oral cavity, lubrication of food, taste of food, and speech. Saliva is produced in 
secretory cells called acini. There are three different types of acini and each is 
characterized by the composition of the cell secretions. Serous cells release saliva that 
is abundant in several proteins but lacks mucin protein. Mucous cells secrete saliva-
containing mucin proteins (6). Seromucous cells secrete a combination of both mucous 
and serous saliva. Once the saliva is secreted from these cells, it is transported through 
intercalated ducts, small excretory ducts, and then through a larger excretory duct that 
opens into the mouth (6). Excretory ducts are lined with columnar epithelium, cuboidal 
cells surround the intercalated ducts, and columnar cells make up the striated duct.  As 
the saliva passes through these ducts, additional proteins, such as Immunoglobulin A 
and lysozyme, from the ductal cells are secreted into the saliva. Myoepithelial cells 
contract and help secretory cells release the saliva while promoting salivary flow 
through the ducts. 
 Salivary glands are subdivided into the major and minor glands. The major 
salivary glands consist of three pairs of glands that are located around the oral cavity. 
The largest are the parotid glands that are located in directly below the ears along the 
jaw. Saliva is exported from the gland directly across from the crowns of the second 
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maxillary molars via Stensen’s duct, a 5 cm duct connecting the gland to the oral cavity.  
Secretions from the parotid glands are exclusively serous. The sublingual gland is 
located underneath the floor of the mouth and are the smallest of the major salivary 
glands. These glands open to the oral cavity via 8-20 excretory ducts and secrete only 
mucous saliva (6). The submandibular glands are also located in the floor of the month 
but are adjacent to the mandibular bone. Saliva is secreted via the Warthon’s duct that 
opens into the floor of the mouth.  This gland secrets seromucous saliva but contains a 
higher percentage of serous acini then mucous acini. The oral cavity also contains 600-
1,000 minor salivary glands that can be found on the tongue, inside of the cheek, lips, 
floor of the mouth, and the hard palate (6). Secretions from these glands are 
predominately mucous with the exception of von Ebner’s glands, which are exclusively 
serous.  
Salivary Gland Cancer 
Salivary gland cancers are rare accounting for 2-6.5% of all head and neck 
cancers with annual incidence of 2.2-3.0 cases per 100,000 people in the United States 
(7-9). Tumors can originate in either the major or minor salivary glands. Approximately 
80% of these tumors arise in the parotid gland, 15% arise in the submandibular gland, 
and 5% arise in the minor and sublingual salivary glands (10). Males have a 51% higher 
rate of incidence over females, although both tend to develop the cancer within the fifth 
decade of life (11). While little is known about the pathogenesis of salivary gland 
cancers, research has shown that radiation exposure is a risk factor and suggests that 
occupation exposures, viruses, UV light, alcohol, and tobacco may also be involved (12-
14). As much as 75% of salivary masses are benign. However, presentation of both 
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malignant and benign tumors is similar making diagnosis and treatment very 
challenging. Malignant salivary gland tumors are markedly heterogeneous including 24 
histologic subtypes, generating significant challenges in diagnosis, prognosis, and 
treatment (9). The following discussion is centered on mucoepidermoid carcinomas and 




Figure II.1. Schematic representation of a salivary gland indicating putative areas of origin for 
mucoepidermoid carcinomas and adenoid cystic carcinomas. Adapted by authors from Bell et 
al. Salivary gland cancers: biology and molecular targets for therapy. Curr Oncol Rep 
2012;14(2):166–174. 
Mucoepidermoid Carcinoma 
Mucoepidermoid carcinoma (MEC) is the most common salivary gland 
malignancy and represents approximately 5-15% of all salivary gland tumors and 30-
35% of all malignant salivary gland tumors (8,15-21). These tumors occur in both the 
major and minor salivary gland glands and are mostly comprised of epidermoid, 
mucous, and intermediate cells types. The epidermoid cells are polygonal in shape and 
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characterized by keratinization and intercellular bridges. Mucous cells very in size but all 
stain positively for mucin proteins. Intermediate cells are thought to functions as 
progenitor cells for epidermoid and mucous cells and are often basal-like in 
appearance. Mucoepidermoid carcinomas also contain a variety of other cell types 
including squamous, clear, columnar, and other uncommon cell types (22-28). They are 
extralobular tumors and are believed to originate in the excretory duct (22,24). 
Diagnosis of mucoepidermoid carcinoma is based on the presence of both, 
histological and cytogenetic abnormalities. These tumors are categorized into three 
grades depending on the amount of cyst formation, the degree of cytological mutation, 
and the relative number of epidermoid, mucous, and intermediate cell types. Low-grade 
tumors tend to have a minimal amount of cytological mutation, a high population of 
mucous cell, and noticeable cyst formation. High-grade tumors contain large areas of 
intermediate and squamous cells that demonstrate increased mitotic activity. 
Intermediate-grade tumors manifest a combination of both low and high-grade 
characteristics. Additional unfavorable histologic factors include perineural invasion, 
necrosis, increased mitotic rate, angiolymphatic invasion, anaplasia, infiltrative growth 
pattern, and the presence of a cystic component (27) However, this grading system is 
often variable making reproducibility difficult (28). Low and intermediate-grade tumors 
are treated using surgical resection while treatment for high-grade tumors includes neck 
dissection and radiation therapy (27). While surgical removal and radiation is often 
successful, a significant number of patients have a recurrence of the disease years later 
(29). For these patients, few treatments options are available as mucoepidermoid 
carcinomas are highly chemo-resistant (12). As a result, chemotherapy is used for 
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patient palliation, although ineffective for actual treatment (30). Improved understanding 
of the pathobiology of the disease leading to rationally designed targeted therapies are 
necessary to improve the outcome of patients with mucoepidermoid carcinoma. 
The most common cytogenetic abnormality in mucoepidermoid carcinoma is a 
recurrent translocation between chromosomes 11 and 19 creating the CRTC1-MAML2 
fusion protein. This translocation is found in 38-81% of mucoepidermoid carcinomas 
and is expressed in all cell types. CREB-regulated transcription coactivator 1 (CRTC1) 
protein activates transcription mediated by cAMP response element-binding (CREB) 
protein (26,31). CREB activated genes regulate cell differentiation and proliferation (32). 
Abnormal expression of these genes has been shown to lead to cancer development 
(32). MAML2 is a coactivator for Notch transcriptional activity that regulates cellular 
differentiation and proliferation (32-33). In the fusion protein, the intracellular Notch-
binding domain of MAML2 is replaced by the CREB binding domain of CRTC1 (12).  
Many studies have shown that presence of CRTC-MAML2 translocation has 
prognostic and diagnostic value (12). Patients with tumors expressing CRTC1-MAML2 
have a greater overall survival as well as a lower risk of recurrence and metastasis 
when compared with fusion-negative tumors (34-35). However, there is a subset of 
high-grade tumors that express CRTC1-MAML2. Studies by Anzick and colleagues 
found that in these high-grade tumors expressing CRTC1-MAML2 and additional 
deletion or hypermethylation of CDKN2A was often found suggesting that the presence 
or absence of both of these abnormalities may serve as a better diagnostic marker (36). 
The role this chimeric protein plays in the pathogenesis of mucoepidermoid carcinoma 
is not known, however, research suggests that this mutation occurs early on during 
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tumor initiation (12,27). Studies have shown that this translocation also appears in a 
subset of Warthin’s tumors and may be linked to the development of these tumors to 
malignant MEC tumors(34-35, 37).  
Adenoid Cystic Carcinoma 
Adenoid cystic carcinoma (ACC) is the second most common malignant salivary 
gland cancer accounting for 10-25% of patients (37-40). Tumors can occur in both 
parotid and submandibular glands as well as the minor salivary glands but are believed 
to arise from the intercalated duct reserve cells found in each of these glands (22,41). 
Adenoid cystic carcinoma is histologically a biphasic cancer indicating that it is 
composed of both epithelial and myoepithelial cells (22, 42-43). Although growth of 
these tumors is slow, the long-term prognosis of these patients is poor. The 5-year 
survival rates are very favorable at 70-90% (39). However, the 15 and 20-year survival 
rates are rather poor at 35-40% and 10% respectively (39-40, 43). Patients with distant 
metastasis have a 5-year survival rate as low as 20% (38). Overall low survival is 
primarily due to the persistence of tumor growth, late recurrence after initial treatment, 
perineural invasion, hematogenous spread and invasion to distant and neighboring 
tissues (44-47). 
Diagnosis and determination of tumor grade is based solely on the predominance 
of one of three histologic growth patterns. The cribriform pattern is easily characterized 
as having numerous pseudocysts giving a “Swiss cheese” like appearance. These 
pseudocysts are mostly made of myoepithelial cells. Ductal areas within this pattern are 
composed of basophilic mucoid material. Tumor cells are cuboidal in shape and are 
small in size. The tubular pattern has similar shaped tumors cells, however, they 
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constitute small ducts in this case. The inside of these ducts is lined with both basal 
myoepithelial cells and luminal ductal cells. Tumors containing a solid growth pattern 
demonstrate large islands of tumors cells with no appearance of cysts of tubules. These 
areas have higher rates of mitosis, necrosis, and variability in cellular shape. 
Predominance of tubular and cribriform growth patterns is associated with less 
aggressive progression and overall longer survival time (27, 40, 43). Tumors consisting 
of >30% solid pattern have the highest grading, and are associated with increased 
aggressiveness and lower survival (43). Though regional metastasis is rare, solid 
tumors have a greater likelihood of metastasizing to the lymph nodes (43). Biomarkers 
of epithelial to mesenchymal transition (EMT) such as Snail1 and Slug have also 
emerged as being associated with increased tumor aggressiveness and may be useful 
in diagnosing adenoid cystic carcinoma (39,40). As all grades are considered 
aggressive, all ACC patients are treated with surgery and radiation (43). Chemotherapy 
treatment has low response rate. However, improved understanding of the biology of 
adenoid cystic carcinomas is leading to clinical trials using targeted therapies known to 
work in other cancer types (43).  
The most common cytological abnormality is a translocation between 
chromosomes 6 and 9 resulting in the MYB-NFIB fusion protein (48). This translocation 
occurs in 33-100% of primary ACC samples and expression is not correlated with 
aggressiveness or grade(31, 48-49). Human nuclear factor 1 (NFI) transcription factor 
contains domains that enable dimerization and DNA-binding. MYB is a transcription 
factor that regulates genes involved in proliferation, differentiation, and apoptosis. The 
t(6;9) translocation typically results in loss of exon 15 in the MYB protein, a site shown 
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to bind micro-RNAs, which in turn negatively regulate expression of MYB (48). This 
leads to overexpression of the fusion protein and overexpression of MYB-induced 
genes, which are involved in cell cycle control, angiogenesis, and apoptosis (48).  
Recent work has shown that c-Kit and epidermal growth factor (EGF) tyrosine kinase 
receptors are also over expressed in adenoid cystic carcinoma (50-55). Although it is 
uncertain the exact mechanism by which overexpression of c-Kit influences cancer 
growth and progression, it has been suggested that it may influence various genetic and 
epigenetic processes. EGFR overexpression is commonly found in cancer and 
promotes cancer development through inhibition of apoptosis and stimulation of 
angiogenesis (10). Imatinib methylate has been successfully used to inhibit tyrosine 
kinase receptors in other cancers such as chronic myelogenous leukemia and 
gastrointestinal stromal tumors (56-58). However, little or no response has been 
observed in adenoid cystic carcinoma (59). Further studies in c-Kit and EGFR may have 
uncovered the reason for this lack of response. Work by the Bell laboratory 
demonstrated that expression of c-Kit is found in the inner ductal cells but negative in 
the myoepithelial cells. Interestingly, the myoepithelial cells showed strong expression 
of EGFR while the ductal cells showed very little expression. This difference in 
expression between cell types could lead to complex patterns of drug response. Further 
research will be necessary to determine the full therapeutic potential of these targets 
(27).   
Cancer Stem Cell Hypothesis 
The cancer stem cell hypothesis states that tumors are initiated and maintained 
by a subpopulation of tumorigenic cells capable of continuous self-renewal and 
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differentiation. The idea that stem cells could initiate cancer progression was first 
suggested over 150 years ago (60-61). However, evidence supporting this hypothesis 
was not shown until Lapidot and colleagues identified a population of stem-like acute 
myeloid leukemic cells with enhanced ability to engraft non-obese diabetic severe 
combined immune-deficient (NOD/SCID) mice (62). Implantation of these CD34+CD38- 
stem cells effectively recapitulated patient tumors whereas CD34+CD38+ and CD34- 
cells showed no such ability. Using limiting dilution assays, they showed that 
approximately 1 in 250,000 cells is a stem cell that can initiate leukemia. This ability was 
sustained in serial transplantation into secondary mice. The Clarke laboratory further 
validated this hypothesis in solid tumors. Implantation of CD44+/CD24-Lin- breast 
cancer cells into NOD/SCID mice also accurately reproduced the original primary tumor 
heterogeneity using as few as 100 cells (63). Isolation using aldehyde dehydrogenase 1 
(ALDH1) activity further enriched this cancer stem cell population (64). Cancer stem 
cells have since been identified in pancreatic, brain, ovarian,  colorectal, head and neck, 
and liver cancer (65-96).  
Further characterization of cancer stem cells has identified several properties 
commonly seen in normal tissue stem cells. Both normal and cancer stem cells are able 
to undergo self-renewal through asymmetric cell divisions, demonstrate multi-lineage 
differentiation, show active expression of telomerase as well as increased expression of 
membrane transporter proteins, and upregulation of anti-apoptotic pathways (97-100). 
While normal and cancer stem cells share common characteristics, the term cancer 
stem cell does not necessarily refer to the cell of origin. Currently there are two 
hypotheses that describe the role of CSC in cancer development (Figure II.2). The 
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original hypothesis states that the first oncogenic hit occurs in normal adult stem cells 
that are then able to differentiate into neoplastic cells. Additional mutations occur as the 
differentiated stem cells divide to form the bulk tumor. An alternative hypothesis states 
that normal differentiated cells, called tumor-initiating cells (T-IC), undergo oncogenic 
mutation and acquire stem cell-like properties enabling them to differentiate and self-
renew. These cells are then able to differentiate into the bulk tumor cells. However, 
work by the Weinberg laboratory suggests that this differentiation is reversible (101). 
Upon depletion of the tumor-initiating cells population, differentiated cells are able to de-
differentiate via epithelial to mesenchymal transition (EMT) pathway (102). 
 
Figure II.2. Schematic representation of two prevailing hypotheses for tumorigenesis, i.e. the 
cancer stem cell hypothesis and the tumor-initiating cell hypothesis. Adapted by authors from 
Reya et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414(6859):105–111.  
In addition to tumor initiation, cancer stem cells play an important role in tumor 
relapse and resistance to chemotherapy. Several studies have shown that this 
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population of cells is resistant to traditional chemotherapeutic and radiation treatments 
(3-4, 103-106). For example, studies have shown that pancreatic cancer stem cells are 
enriched after treatment with gemcitabine and play a major role in tumor growth and 
metastasis (65, 107). Survival and enrichment of these stem cells allows for re-initiation 
of tumor growth resulting in patient relapse. Cancer stem cell survival can be attributed 
to several unique attributes. These cells are typically in G0 making them relatively 
quiescent and endowing them with resistance to chemotherapeutic agents that act in a 
cell cycle-dependent manner (108). Studies have also shown that cancer stem cells 
upregulate DNA damage repair proteins, anti-apoptotic proteins, and transporter 
proteins such as ABCG2 (109-115). For such reasons, the cancer stem cells hypothesis 
is intriguing in the context of salivary gland tumors, which are not responsive to 
chemotherapy treatments. Further understanding of pathways involved in cancer stem 
cell resistance could lead to development of treatments that target this subpopulation of 
cells thereby sensitizing salivary gland tumors to therapies that eliminate the bulk tumor 
population.  
Emerging research also suggests that the stem cell niche and surrounding 
microenvironment enables cancer stem cells to survive chemo and radiation treatments 
as well as to sustain self-renewal and progression of the cancer. The concept of a stem 
cell niche was first suggested by the Morrison laboratory and is defined as a tissue 
microenvironment that is capable of taking up and maintaining the function of stem cells 
(116). A substantial amount of evidence suggests that surrounding cells in the 
microenvironment are capable of signaling and promoting cancer growth via immune 
and stromal cell signaling (117). Work by several groups suggests that signaling from 
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the microenvironment specifically acts to maintain and promote survival and self-
renewal of the CSC in the stem cell niche.  Macrophages play a critical role in the onset 
of inflammation and the recruitment of other immune cells. These cells have also been 
shown to activate epithelial cells via NF-kB signaling, increase expression of genes 
associated with pluripotency thereby maintaining undifferentiated state of the cancer, 
and increase microvasculature production providing tumors with essential nutrients 
(118-121). Endothelial cells have also been shown to play a similar role in the tumor 
microenvironment. Studies in head and neck cancer have shown that cancer stem cell 
survival and self-renewal is increased when exposed to the growth factor milieu 
secreted adjacent endothelial cells (93). Fibroblasts have also been shown to be an 
important component of the microenvironment that helps maintain cancer stem cells. 
Under normal conditions, fibroblasts function to promote wound healing. In cancer, 
however, tumor-associated fibroblasts promote both invasion and angiogenesis as well 
as secrete factors that promote stemness of cancer stem cells (122). Development of 
targeted therapies that disrupt the microenvironment in these stem cells niches could 
inhibit survival and self-renewal properties of cancer stem cells. 
Head and Neck Cancer Stem Cells 
Increasing evidence indicates that the cancer stem cells play an important role in 
the pathogenesis and progression of head and neck squamous cell carcinomas 
(HNSCC). While novel treatments have improved the quality of life of patients 
diagnosed with this cancer, overall survival rates have remained largely unchanged in 
the last few decades, particularly in patients with advanced disease (123-125). Distant 
metastasis, loco-regional disease recurrence, and lack of response to chemotherapy 
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are the primary challenges facing these patients (126-130). As cancer stem cells have 
been implicated in each of these same challenges, further understanding of the biology 
of these cells in the context of HNSCC could lead to targeted treatments that benefit 
patients.  
 Cancer stem cells were first isolated in HNSCC by Prince and colleagues in 2007 
(88). In these experiments, cells sorted for CD44 expression showed increased 
tumorigenicity over the cells that lacked CD44 expression. When implanted in 
NOD/SCID mice, CD44high cells were able to form tumors in 20 out of 31 injections 
whereas the CD44low population only formed 1 tumor out of 40 total injections. Tumors 
generated from CD44high cells were phenotypically diverse for CD44 expression 
indicating that CD44high cells are able to both differentiate in to CD44low cells but also 
self-renew into CD44high cells. Gene expression analysis of CD44high and CD44- 
populations showed that CD44high cells highly expressed Bmi-1 while CD44low cells 
showed no detectable expression of this protein suggesting that CD44 marker enriches 
for cells with stem cell-like properties. However, mice injected with fewer then 5 x 103 
were unable to form tumors indicating that this marker alone may enrich for cancer stem 
cells but not necessarily be sufficient to isolate a pure population of these cells.  
 Later experiments by Clay et al suggest that aldehyde dehydrogenase (ALDH), a 
marker first used in breast cancer, expression may further enrich a cancer stem cell 
population in HNSCC cells (64, 131). ALDH expression was low accounting for about 
1.0-7.8% of the total cell population. ALDHhigh populations were highly tumorigenic 
forming tumors in 7 out of 15 injections with as few as 50-100 cells, and are able to 
replicate the original tumor heterogeneity. Krishnamurthy and colleagues later showed 
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that the combined expression of ALDH and CD44 further enhanced the ability to identify 
the cancer stem cell population (93). Using 1,000 ALDHhighCD44high cells, tumors were 
formed in 13 out 15 injections while only 3 out of 15 tumors were generated when 
10,000 ALDHlowCD44low cells were injected (93).  
 Further characterization of the microenvironment surrounding head and neck 
cancer stem cells suggests the existence of a perivascular niche that supports stem cell 
maintenance and resistance to anoikis (93). They observed that approximately 80% of 
ALDHhigh cells are located within 100-µm radius of neighboring blood vessels. This area 
was identified as the perivascular niche as it was calculated to be the area of diffusion 
of oxygen and nutrients from the blood vessels. Exposure to endothelial-cell secreted 
factors enhanced the expression of ALDH, CD44, and stemness marker Bmi-1, as well 
as a 3-fold increase in the number of orospheres in low attachment conditions 
suggesting that endothelial cells play an important role in stem cell self-renewal. 
Ablation of endothelial cells via an artificial caspase-based death switch drastically 
decreased the ALDHhighCD44high positive population. Later experiments indicated that 
endothelial cell regulation of cancer stem cells is in part mediated by IL-6 (93). Although 
not as potent as full endothelial cell-conditioned media, treatment with rhIL-6 increased 
in vitro orosphere formation and the tumorigenic potential of cancer stem cells 
(unpublished observations).  
Studies by Campos and colleagues found that upon induction by anchorage and 
serum starvation, cancer stem cells exposed to endothelial cell-conditioned media were 
more resistant to anoikis (132). This occurred via the PI-3/Akt pathway that is known to 
regulate proliferation and cell survival. Endothelial cell-conditioned media induces 
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phosphorylation of Akt. Blocking VEGF decreased Akt phosphorylation. Together, these 
studies provide evidence of a microenvironment that is capable of supporting and 
maintaining the cancer stem cell population. Targeting the crosstalk between cancer 
stem cells and other cells of their supportive niche may provide an effective way to 
abrogate the tumorigenic function of these cells. 
Salivary Gland Cancer Stem Cells 
The cancer stem cell hypothesis has yet to be fully explored in salivary gland 
tumors. However, initial experiments by Sun and colleagues indicate that ALDH isolates 
cancer stem cells in adenoid cystic carcinomas (133). Using a patient derived xenograft 
model, serially diluted ALDHhigh and ALDHlow cells were injected into NOD/SCID mice. 
Under these conditions, 24 out of 60 injections of 100-1,000 ALDHhigh cells were able to 
form tumors. Notably, injection of as few as 50 ALDHhigh cells was able to generate a 
tumor.  No tumors were observed in ALDHlow injected mice at similar dilutions of cells. In 
total, 56/122 injections of ALDHhigh cells formed tumors were only 5/126 injections of 
ALDHlow cells were able to form tumors. ALDHhigh cells also showed an increased ability 
to form spheres when plated in low-attachment plates as well as increased invasion in a 
Matrigel-coated Boyden chamber. ALDHhigh cells infected with luciferase vectors 
showed increased ability to metastasize when compared to ALDHlow cells. Collectively, 
these data suggest that ALDH may indeed isolate a more tumorigenic population of 
cells. 
Zhou and colleagues further characterized the expression of ALDH in adenoid 
cystic carcinomas (134). Immunohistochemical analysis of ALDH expression in human 
tumors indicated three staining patterns. Approximately 63% of patient’s samples 
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showed staining only in the stromal cells, 26% had neither stromal nor epithelial 
staining, and 11% had both epithelial and stromal staining. Normal salivary gland 
showed staining for ALDH only in epithelial cells. However, these different patterns had 
no correlation to tumor size, perineural invasion, or overall survival. Additional 
experiments are needed to further verify ALDH as a cancer stem cell marker in adenoid 
cystic carcinoma. Studies by Fujita and colleagues found overlapping populations of 
CD44 and CD133 markers in adenoid cystic carcinomas.  However, whether or not 
these markers isolate and more tumorigenic population of cells has yet to be testing in 
sphere or in vivo models (135). 
As previously discussed, EGFR is commonly upregulated in adenoid cystic 
carcinoma tumors (10). Research in other cancer types has demonstrated the role of 
EGF signaling in the self-renewal of CSC suggesting this pathway may also play a role 
in the self-renewal of CSC in adenoid cystic carcinoma. A clinical trial in breast cancer 
determined that treatment with lapatinib, an EGFR/HER2 inhibitor, substantially reduced 
the CD44high/CD24low stem cell population (136). In the same study, the authors showed 
that lapatinib decreased mammosphere formation in vitro (136). Korkaya and 
colleagues further confirmed these results (137). They showed that HER2 signaling 
significantly increased the Aldefluor stem cell population of normal mammary epithelial 
cells (NMECs) and increased mammosphere formation. Interestingly, HER2 positive but 
Aldefluor negative cells were unable to form mammospheres. Notably, this concept was 
also confirmed in head and neck squamous cell carcinoma models (138). HNSCC cells 
lines transfected with EGFRvIII demonstrated increased proliferation, decreased 
sensitivity to cisplatin treatment, and increased the CD44high population. The role of 
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EGFR in adenoid cystic carcinoma CSC has yet to be investigated but may be 
important for understanding the self-renewal and tumorigenicity of these cells.  
In addition to EGFR, c-kit (CD117) is also commonly upregulated in adenoid 
cystic carcinoma (50-55). Interestingly, c-kit tyrosine receptor kinase binds stem cell 
factor (SCF) to trigger pathways involved in the maintenance of progenitor cells (139). 
Interestingly, this cell surface receptor is commonly used to isolate progenitor cells in 
submandibular glands (140). Expression of c-kit in these sample overlaps with 
expression of other commonly knows stem cell markers, (e.g. Nanog, Oct3/4), 
suggesting it plays an important role in the maintenance of stem cell properties (143). 
As a marker of stem cells in normal salivary gland, c-kit could also be a potential marker 
for CSC in adenoid cystic carcinoma as well. Studying the role of this protein in the 
context of CSC could provide useful insight into the isolation and regulation of these 
cells. 
Unpublished work for our group also suggests the presence of CSC in 
mucoepidermoid carcinoma. Using the mucoepidermoid carcinoma cells lines that our 
laboratory has generated, we are able to generate orospheres (Figure III.3). These 
structures, first characterized in head and neck squamous cell carcinoma CSC, exploit 
the fact that stem cells possess anchorage independent growth (141-143). By culturing 
these cells in low attachment and serum free conditions, we are able to generate 
orospheres in unsorted cells suggesting that these cell lines do indeed contain a unique 
stem cell population. Cells cultured in 10% FBS were unable to form spheres and 
demonstrated lower viability in low attachment compared to cells cultured under serum-
free conditions, suggesting that we have indeed isolated a stem cell-like population. 	
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Figure III.3. Photomicrographs of spheres formed by mucoepidermoid carcinoma cells at 
passage 62 or 87 cultured in ultra-low attachment plates indicating the existence of cells 
exhibiting stem-like behavior in this cell line.  
 
Conclusions 
The most pressing clinical challenges in treatment of salivary gland cancers are tumor 
resistance to chemotherapy and the lack of targeted treatments that are safe and 
effective in these tumors. While surgery and radiation treatment successfully cure a 
subset of these patients, many present recurrent and/or metastatic disease several 
years later leading to significant morbidity. Cancer stem cells have been shown to be 
resistant to chemotherapy and radiation treatments leading to tumor relapse. These 
cells are also implicated in the progression and development of metastasis. It is 
possible that cancer stem cells are involved in the processes that result in the late 
recurrence or metastases that are frequently observed in patients with salivary 
malignancies. Therefore, selective targeting of this rare sub-population of tumorigenic 
cancer stem cells could inhibit tumor recurrence and metastasis, and improve patient 
survival and quality of life.  
  
concept was also confirmed in head and neck squamous cell carci-
noma models.138 HNSCC cells lines transfected with EGFRvIII dem-
onstrated increased proliferation, decreased sensitivity to cisplatin
treatment, and increased the CD44high population. The role of EGFR
in adenoid cystic carcinoma CSC has yet to be investigated but may
be important for understanding the self-renewal and tumorigenic-
ity of these cells.
In addition to EGFR, c-kit (CD117) is also commonly upregu-
lated in adenoid cystic carcinoma. Interestingly, c-kit tyrosine
receptor kinase binds stem cell factor (SCF) to trigger pathways in-
volved in the maintenance of progenitor cells.139 Interestingly, this
cell surface receptor is commonly used to isolate progenitor cells in
submandibular glands.140 Expression of c-kit in these sample over-
laps with expression of other commonly knows stem cell markers,
(e.g. Nanog, Oct3/4), suggesting it plays an important role in the
maintenance of stem cell properties.143 As a marker of stem cells
in normal salivary gland, c-kit could also be a potential marker
for CSC in adenoid cystic carcinoma as well. Studying the role of
this protein in the context of CSC could provide useful insight into
the isolation and regulation of these cells.
Unpublished work for our group also suggests th presence of
CSC in mucoepidermoid carcinoma. Using the mucoepidermoid
carcinoma cells lines that our laboratory has generated, we are able
to generate orospheres (Fig. 3). These structures, first characterized
in head and neck squamous cell carcinoma CSC, exploit the fact
that stem cells possess anchorage independent growth.141–143 By
culturing these cells in low attachment and serum free conditions,
we are able to generate orospheres in unsorted cells suggesting
that these cell lines do indeed contain a unique stem cell popula-
tion. Cells cultured in full 10% FBS were unable to form spheres
and demonstrated lower viability in low attachment compared to
cells cultured in serum free suggesting that our conditions do in-
deed isolate a stem cell-like population.
Conclusions
The most pressing clinical challenges in treatment of salivary
gland cancers are tumor resistance to chemotherapy and the lack
of targeted treatments that are safe and effective in these tumors.
While surgery and radiation treatment successfully cure a subset
of these patients, many present recurrent and/or metastatic dis-
ease several years later leading to significant morbidity. Cancer
stem cells have been shown to be resistant to chemotherapy and
radiation treatments leading to tumor relapse. These cells are also
implicated in the progression and development of metastasis. It is
possible that cancer stem cells are involved in the processes that
result in the late recurrence or metastases that are frequently ob-
served in patients with salivary malignancies. Therefore, selective
targeting of this rare sub-population of tumorigenic cancer stem
cells could inhibit tumor recurrence and metastasis, and improve
patient survival and quality of life.
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ALDH/CD44 identifies uniquely tumorigenic cancer stem cells 




A small sub-population of cells characterized by increased tumorigenic potential, ability 
to self-renew and to differentiate into cells that make up the tumor bulk, has been 
characterized in some (but not all) tumor types. These unique cells, named cancer stem 
cells, are considered drivers of tumor progression in these tumors. The purpose of this 
work is to understand if cancer stem cells play a functional role in the tumorigenesis of 
salivary gland mucoepidermoid carcinomas. Here, we investigated the expression of 
putative cancer stem cell markers (ALDH, CD10, CD24, CD44) in primary human 
mucoepidermoid carcinomas by immunofluorescence, in vitro salisphere assays, and in 
vivo tumorigenicity assays in immunodeficient mice. Human mucoepidermoid carcinoma 
cells (UM-HMC-1, UM-HMC-3A, UM-HMC-3B) sorted for high levels of ALDH activity 
and CD44 expression (ALDHhighCD44high) consistently formed primary and secondary 
salispheres in vitro, and showed enhanced tumorigenic potential in vivo (defined as time 
to tumor palpability, tumor growth after palpability), when compared to ALDHlowCD44low 
cells. Cells sorted for CD10/CD24, and CD10/CD44 showed varying trends of 
salisphere formation, but consistently low in vivo tumorigenic potential. Finally, cells 
sorted for CD44/CD24 showed inconsistent results in salisphere formation and 
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tumorigenic potential assays when different cell lines were evaluated. Collectively, these 
data demonstrate that salivary gland mucoepidermoid carcinomas contain a small 
population of cancer stem cells with enhanced tumorigenic potential that are 
characterized by high ALDH activity and CD44 expression. These results suggest that 
patients with mucoepidermoid carcinoma might benefit from therapies that ablate these 
highly tumorigenic cells. 
Introduction 
Advanced salivary gland mucoepidermoid carcinoma (MEC) is a relentless and typically 
fatal disease. Mucoepidermoid carcinoma is the most common malignant salivary gland 
cancer, accounting for 5-15% of all salivary tumors and 30-35% of malignant salivary 
tumors (1-7). These tumors arise in both the major and minor salivary gland and are 
characterized by the presence of mucous, epidermoid, and intermediate cells types. 
Low-grade tumors show noticeable cyst formation, a higher portion of mucous cells, and 
minimal cytological mutation while high-grade tumors are characterized by large 
concentrations of intermediate and squamous cells as well as increased mitotic activity. 
Current treatment consists of surgical resection with or without radiation, depending on 
tumor grade. Patients presenting with recurrent, locally invasive, or metastatic tumors 
do not have effective treatment options (8). Understanding the pathobiology of this 
cancer, particularly mechanisms involved in resistance to therapy, is critical to improve 
the survival and the quality of life of patients with mucoepidermoid carcinoma. 
 The cancer stem cell (CSC) hypothesis states that tumors contain a small sub-
population of multipotent cells that are capable of self-renewal and differentiation, and 
are uniquely tumorigenic. These cells initiate and maintain tumor growth and 
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progression in several cancers including breast, head and neck, pancreatic, liver, 
ovarian, colorectal, and brain cancers (9-16). However, it is unclear if cancer stem cells 
play a functional role in the pathobiology of mucoepidermoid carcinoma. Importantly, 
cancer stem cells are thought to be resistant to chemotherapy and radiation due, at 
least in part, to slower proliferation rates and differential function of transporter proteins 
(17-19). It is believed that survival of these cells after treatment enables tumor relapse. 
Identification and understanding of how these cells function in mucoepidermoid 
carcinomas might lead to more effective therapies. 
 Isolation of cancer stem cells can be accomplished using protein markers that 
are differentially expressed in stem cells compared to the non-cancer stem cell 
population. One such marker is aldehyde dehydrogenase (ALDH)-1, a cytosolic enzyme 
that oxidizes aldehydes into carboxylic acids (20-22). ALDH1 is thought to play an 
important role in hematopoietic stem cell fate determination by regulating the conversion 
of retinol into retinoic acid (23). Importantly, ALDH1 identifies cancer stem cells in 
breast, lung, head and neck, colorectal, ovarian, pancreatic, bladder, prostate, and 
cervical cancers (10, 24-33). Another surface marker protein used extensively to identify 
cancer stem cells is CD44, a transmembrane glycoprotein. This protein functions in key 
cellular processes regulating survival, differentiation, growth, and cell motility (34). 
CD44 has been used as a stem cell marker in breast, head and neck, pancreatic, 
prostate, and colorectal cancers (34). The cell adhesion protein, CD24, is also an 
important stem cell marker used in breast, pancreatic, and colorectal cancers (9, 35, 
36). Interestingly, cancer stem cells are identified within the CD24low population in 
breast tumors (9), while in pancreatic cancer they are identified within the CD24high 
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population (35). And finally, the metallo-endoprotease CD10, a diagnostic marker in 
several tumors, has been implicated in invasion is breast, gastric, and colorectal cancer 
(37). This protein plays an important role in the maintenance of mammary gland stem 
cells, suggesting that it could also serve as a marker for stem cells in glandular 
malignancies (37).  
 While cancer stem cells have been identified and well characterized in several 
tumors, their presence and functional role has not been investigated in salivary gland 
mucoepidermoid carcinomas. Here, we used cell lines and xenograft models recently 
generated in our laboratory (38) to screen for cancer stem cells using several 
combinations of ALDH, CD44, CD24, and CD10 markers. Our findings indicate that 
cancer stem cells play a functional role in mucoepidermoid carcinoma, and that these 
cells can be isolated using the ALDH/CD44 marker combination. In contrast, 
combinations of CD44, CD24, and CD10 did not identify tumorigenic cells consistently. 
Together, these results unveil the function of a uniquely tumorigenic population of 
cancer stem cells in the pathogenesis of mucoepidermoid carcinomas. 
Materials and Methods 
 
Cell Culture 
Human salivary gland mucoepidermoid carcinoma cell lines (UM-HMC-1, UM-HMC-3A, 
UM-HMC-3B) previously characterized in our laboratory (38) were cultured in high 
glucose Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen, Carlsbad, CA, USA) 
supplemented with penicillin/streptomycin (Invitrogen), L-glutamine (Invitrogen), 10% 
FBS (Invitrogen), 20 ng/ml epidermal growth factor (EGF; Sigma-Aldrich, St. Louis, MO, 
USA), 400 ng/ml hydrocortisone (Sigma-Aldrich), and 5 µg/ml insulin (Sigma-Aldrich) 
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[38]. Cells were passaged using 0.05% trypsin/EDTA (Invitrogen). Primary human 
dermal microvascular endothelial cells (HDMEC; Lonza, Walkersville, MD, USA) were 
cultured using endothelial growth medium (EGM2-MV; Lonza).  
Flow Cytometry 
Trypsinized cells were filtered using 5 ml polystyrene round-bottom tumor with cell 
strainer caps (BD Pharmingen). Single cell suspensions of 2x106 cells/ml were prepared 
and incubated with 5 µl Aldefluor® substrate (BAA), or 5 µl of the inhibitor 
diethylaminobenzaldehyde (DEAB) for 40 minutes at 370C, using the Aldefluor kit 
(StemCell; Vancouver, Canada). Cells were exposed to anti-CD44 (APC-Cat #559942, 
PE-Cat #550989), anti-CD24 (FITC-Cat #555427; BD Pharmingen), or anti-CD10 (APC-
Cat #340923; BD Pharmingen) for 30 minutes at 40C. Positive anti-HLA-ABC (PE-Cat 
#560168; BD Pharmingen) was used to separate human cells from mouse cells, and 7-
AAD (Cat #00-6993-50; eBiosciences) staining was used to verify cell viability. 
Salisphere Assay 
Non-adherent spheres of salivary mucoepidermoid carcinoma cells (salispheres), 
previously characterized in normal salivary cells [45], were cultured in DMEM/F-12 
(Invitrogen) supplemented with 20 ng/ml EGF (Sigma-Aldrich), 20 ng/ml basic fibroblast 
growth factor (bFGF; Millipore), 1% penicillin/streptomycin (Invitrogen), 1% glutamax 
(Invitrogen), 1% N-2 supplement (Invitrogen), 1 µM dexamethasone (Sigma-Aldrich), 
and 10 µg/ml insulin (Sigma-Aldrich) (39). Cells were counted, diluted to 2,000 per 1.5 
ml, and added to 6-well ultra-low attachment plates (Corning; Corning, NY, USA). For in 
vitro passaging, salispheres were collected and exposed to 0.25% trypsin for 5-10 
minutes, and then mechanically dissociated. The trypsin was neutralized using a trypsin 
	 46	
neutralizing solution (TNS; Lonza). Colonies of 50 cells or more were considered 
salispheres.  
In vivo studies 
Single cell suspensions of sorted mucoepidermoid carcinoma cells (UM-HMC-1, UM-
HMC-3A, UM-HMC-3B) were seeded in biodegradable scaffolds with 9 x 105 human 
dermal microvascular endothelial cells (HDMEC; Lonza) and bilaterally implanted in the 
subcutaneous space on the dorsum of severe combined immunodeficient (SCID) mice 
(CB-17 SCID; Charles River, Wilmington, MA, USA), as we have shown (39, 40). 
Second generation tumors were generated by transplanting cells retrieved from the 
digestion of the first generation tumors in secondary mice. Tumors were minced into 
small fragments and digested using 1X collagenase-hyaluronidase (Stem Cell 
Technologies; Vancouver, BC, Canada) at 370C for 45 minutes, pipetting up and down 
every 15 minutes. Digested cells and tissues were passed through a 40-µm sieve 
(Fisher) and neutralized using 3-5 ml FBS. Cell suspensions were centrifuged and 
incubated with AKC lysis buffer (Invitrogen) for 1 minute, centrifuged, counted, and 
subjected to flow cytometry. For the studies designed to understand the effect of in vitro 
cell attachment conditions on the tumorigenic potential in vivo, cells were cultured with 
serum-free medium as salispheres (as described above), or in normal attachment 
conditions. After 7 days, attached cells were retrieved, 200,000 cells were seeded per 
biodegradable scaffold and transplanted into mice, as also described above. 
Alternatively, the salispheres were collected but not dissociated (to maintain the sphere 
structure), and 200,000 cells/scaffold were transplanted into mice. Tumor growth was 
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measured every seven days with calipers, and mice were euthanized when the tumors 
reached a maximum of 2,000 mm3. 
Western Blot 
UM-HMC-3A and UM-HMC-3B were sorted for ALDHhighCD44high. As controls, we 
combined the ALDHhighCD44low, ALDHlowCD44high, and ALDHlowCD44low as non-CSC 
cell population. NP-40 lysis buffer was used to prepare whole cell lysates that were 
resolved using PAGE. Membranes were probed using antibodies a 1:1000 dilution 
against human mTor, p-mTor, Akt, p-Akt, S6K, p-S6K (Cell Signaling; Beverly, MA, 
USA); 1:2000 dilution of EGFR, a 1:1000 dilution of p-EGFR, and beta-actin (Santa 
Cruz Biotechnology; Santa Cruz, CA, USA) overnight at 40C.   
Immunofluorescence Staining 
Cells were cultured in Lab-Tek® 4-well chamber slides (Thermo Scientific) overnight, 
fixed with 2% formaldehyde and 0.2% glutaraldehyde for 20 minutes, incubated in 0.1% 
Triton-X 100 for 10 minutes, and then in 0.3% hydrogen peroxide for 10 minutes. 
Paraffin-embedded sections were deparaffinized and treated with a 1X antigen retrieval 
solution in citrate buffer (Dako; Carpinteria, CA, USA) at 45-980C for 60 minutes 
followed by treatment with 3% hydrogen peroxidase for 10 minutes. Rabbit anti-human 
ALDH1A1 (Abcam; Cambridge, England) was incubated overnight and labeled with 
Alexafluor 488 (Anti-Rabbit, Invitrogen) the following day. Cells were incubated with 
mouse anti-human CD44 (Thermo Scientific), rabbit anti-human CD10 (Abcam), and 
mouse anti-CD24 (Abcam) for 1 hour then labeled with Alexafluor 594 (anti-mouse, 
Invitrogen), Alexafluor 488 (anti-rabbit, Invitrogen), and Alexafluor 488 (anti-mouse, 
Jackson ImmunoResearch) respectively. We analyzed tissues from diagnostic incisional 
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biopsies taken from 12 patients. A pathologist graded the samples according to WHO 
standards, but the tentative grades are subjective and observer-dependent.  
Statistical analyses 
Statistical analysis of in vitro data was performed using either a t-test or one-way 
ANOVA followed by post-hoc tests (SigmaStat 2.0 software; SPSS, Chicago, IL). Time 
to failure data was analyzed using the Kaplan-Meier method and the log-rank test. We 
employed linear mixed model regression to analyze the repeated measurements data 
on each tumor. Model fixed effects included time, marker, the interaction of time and 
marker, and model random effects included both mouse and tumor position. For all 
models a continuous autoregressive correlation structure was used, which assumes 
more correlated variances among temporally proximate observations. A log-
transformation of the outcome variable (tumor volume) was to account for exponential 
increase of tumor volumes. Tumor growth rate since palpability (200 mm3) was 
measured, and we controlled for size differences of the tumor at first palpability. 
Analysis was performed using the “nlme” package in the statistical software program R 
v 3.1.0. (41). 
Results 
Characterization of putative stem cell markers in human mucoepidermoid 
carcinomas 
To investigate the expression patterns of cancer stem cell markers in human 
mucoepidermoid carcinomas, we obtained tissue sections from diagnostic incisional 
biopsies and performed immunofluorescence staining. We focused on stem cell 
markers that have been verified in other glandular malignancies, i.e. ALDH, CD44, 
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CD24, and CD10. We found that 7 of the 12 samples showed positive staining for all 
four markers. Ten of 12 samples stained positively for ALDH1, 12 of 12 samples stained 
for CD44, 9 of 12 samples stained for CD10, and 10 of the 12 samples stained for CD24 
(Table III.1). Interestingly, we observed low staining levels for each one of these 
markers in normal salivary glands, when qualitatively compared with mucoepidermoid 
carcinomas (Figure III.1A).  
Table III.1. Patient demographic and expression of CSC markers in human salivary gland 
mucoepidermoid carcinomas. 
 
When less aggressive, cystic tumors were compared to more aggressive, solid tumors, 
we saw an increase in ALDH1 expression in the solid tumor (Figure III.1A). In contrast, 
CD44 stained highly in both tumor types (Figure III.1A). CD10 and CD24 showed 
differential expression between the cystic and solid tumor types. CD10 showed 
expression in both the cystic and solid tumors, however, more positive staining was 














ALDH CD44 CD10 CD24
1 F 49 Hard palate Mixed Intermediate 10 Absent Present Absent Present
2 M 46 Jugal mucosa Solid High 8 Present Present Absent Present
3 F 24 Hard palate Solid Intermediate 30 Present Present Present Present
4 F 14 Hard/soft palate Solid High 50 Present Present Present Present
5 F 29 Palate Mixed High 20 Present Present Present Present
6 F 26 Palate Cystic Low 15 Present Present Present Present





Solid High 40 Present Present Present Present
9 M 62 Jugal mucosa Cystic High 12 Present Present Absent Present
10 F 63 Hard palate Solid Intermediate 15 Present Present Present Absent
11 F 67 Palate Solid Intermediate 15 Present Present Present Present
12 F 55 Hard palate Mixed High 20 Present Present Present Present
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seen in the solid tumor (Figure III.1A). Interestingly, cells with high CD10 expression 
were localized mainly on the outside edge near the stroma suggesting that these cells 
may be important in intercellular signaling with the microenvironment. Tumor cells in 
these sections showed positive staining for CD24. However, the solid tumor areas 
showed more positive staining when compared to the cystic areas (Figure III.1A). 
Together, these results suggest that ALDH1, CD44, CD10, and CD24 are highly 
expressed in salivary gland mucoepidermoid carcinoma when compared to normal 
salivary gland and that expression of ALDH1, CD10, and CD24 may be differentially 
regulated in more aggressive cell types.  
We also performed immunofluorescence staining on three human salivary 
mucoepidermoid carcinoma cell lines (UM-HMC-1, UM-HMC-3A, UM-HMC-3B) plated 
in Lab-Tek glass slides. We observed that ALDH1 staining is present but in only few 
cells (Figure III.2). In contrast, CD44 stained very highly in all cell lines evaluated 
(Figure III.2). CD10 stained positively but its expression was variable among the cell 
lines (Figure III.2). While UM-HMC-3B stained highly for CD10, UM-HMC-1 showed 
significantly less CD10 expression. UM-HMC-3A showed moderate staining when 
compared to UM-HMC-1 and UM-HMC-3B. Finally, all three cell lines showed similar 
levels of expression of CD24. 
Characterization of putative stem cell markers in mucoepidermoid carcinoma cell 
lines 
We used flow cytometry to screen three human salivary mucoepidermoid 




Figure III.1: Characterization of putative stem cell markers in human mucoepidermoid 
carcinoma specimens. A. Representative photomicrographs of H&E and immuno uorescence 
images of tissue sections derived from patients with normal salivary gland; a low-grade, cystic 
tumor; or a high-grade, solid tumor. ALDH1, CD10, and CD24 are stained in green while CD44 
is stained in red. H&E images were taken at 40X and immuno uorescence images were taken at 
400X. B. Flow cytometry analysis of three cell lines (UM- HMC-1, UM-HMC-3A, UM-HMC-3B) 
stained for ALDH/CD44, CD44/CD24, CD10/CD44, and CD10/CD24. CD44-APC staining is 
shown on the horizontal axis while ALDH staining is shown on the vertical axis. CD44-PE is 
shown on the horizontal axis and CD10-APC is in the vertical axis. CD24-FITC is shown on the 
horizontal axis and CD10-APC or CD44-APC is shown on the vertical axis. C. Graph depicting 
the percentage of positive cells for ALDH, CD44, CD10, and CD24.  
 
cell markers. UM-HMC cells consistently showed greater than 90% positive staining for 
CD44. In contrast, the percentage of ALDH high cells in UM-HMC-1 was only 4.4%, and 
in UM-HMC-3A and UM-HMC-3B was even lower (2.8%, 0.7% respectively) (Figure 
III.1B and 1C). When these two markers were combined, the most common population 
of cells was consistently ALDHlowCD44high (Figure III.1B).  
UM-HMC cells showed variable staining for CD10 and CD24. UM-HMC-1 and 
UM-HMC-3B stained highly for CD24, while UM-HMC-3A showed less staining (Figure 
III.1B and 1C). CD10 staining was highest in UM-HMC-3B when compared to UM-HMC-
3A and UM-HMC-1 cells (Figure III.1C). The combination of CD10/CD24 in UM-HMC-1 
showed the majority of cells as CD10lowCD24high. In UM-HMC3A cells, most cells 
stained CD10lowCD24low followed by CD10lowCD24high, CD10highCD24low, and 
CD10highCD24high. UM-HMC-3B cells stained highly for CD10highCD24high cells followed 
by CD10lowCD24high, CD10highCD24low, and CD10lowCD24low, showing an inverse 
expression profile when compared with UM-HMC-3A (Figure III.1B). When stained for 
combination CD44/CD24, UM-HMC-3B and UM-HMC-1 stained predominately 
CD44highCD24high, while UM-HMC-3A stained mainly CD44highCD24low. While all cell 
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Figure III.2. Characterization of putative stem cell markers in human mucoepidermoid 
carcinoma cell lines. A. Representative photomicrographs of immunofluorescence staining for 
ALDH, CD44, CD10, or CD24 of a panel of mucoepidermoid carcinoma cells (UM-HMC-1, UM-
HMC-3A, UM-HMC-3B) cultured in Lab-Tek chamber slides. Images were taken at 200X.   
 
lines stained positively for CD44, CD24 expression was variable (Figure III.1B and 1C). 
CD10/CD44 combination also showed differential expression among cell lines. UM-
HMC-1 and UM-HMC-3A showed low staining for CD10 and therefore, the most 
prevalent population in both lines was CD10lowCD44high. UM-HMC-3B staining positively 
for CD10highCD44high but also showed staining in the CD10lowCD44high population 
(Figure III.1B). 
In summary, all UM-HMC cell lines showed positive staining for the four markers 
studied here. We observed that all cell lines consistently presented low ALDH activity 
and high CD44 expression. On the other hand, the expression of CD10 and CD24 was 













In vitro salisphere analysis of mucoepidermoid carcinoma cell lines 
To begin the functional characterization of these putative marker combinations, we 
screened the UM-HMC cell lines for salisphere formation under ultra-low attachment, 
serum-free conditions. The three cell lines studied here formed salispheres. However, 
UM-HMC-1 cells generated less salispheres than UM-HMC-3A and UM-HMC-3B under 
these culture conditions (Figure III.3A and 3B). To evaluate the effectiveness of each 
specific marker combination to select cells with enhanced self-renewal capacity, primary 
salispheres were dissociated and passaged into secondary salispheres (Figure III.3C). 
Interestingly, we observed a trend for increasing number of salispheres with passaging 
when unsorted cells were evaluated (Figure III.3A).  
To begin to understand the ability of marker combinations to select for cancer stem 
cells, we FACS-sorted the UM-HMC-3A and UM-HMC-3B cell lines according to ALDH 
activity, CD10, CD24, and/or CD44 protein expression. Sorted cells were plated in ultra-
low attachment conditions and grown for seven days before the number of salispheres 
was determined. Salispheres were then dissociated and allowed to grow for additional 
seven days under the same culture conditions. The ALDHlowCD44low cells showed little 
to no salisphere growth. In contrast, both the ALDHhighCD44high and ALDHlowCD44high 
populations showed significant salisphere formation in primary and secondary cultures 
(Figure III.4A, Table III.2). Because the ALDHhighCD44low population is so rare, we were 




Figure III.3. Sphere analysis of unsorted HMC cells. A. Graph depicting the average number 
of sphere formed per well in a 6-well low attachment plate in UM-HMC-1, UM-HMC-3A, and 
UM-HMC-3B cells. B. Images of UM-HMC-1, UM-HMC-3A, and UM-HMC-3B primary spheres 
in low attachment culture. Images were taken at 40X and 100X. C. Images of UM-HMC-1, UM-
HMC-3A, and UM-HMC-3B secondary spheres in low attachment culture. Images were taken at 



















Table III.2: In-Vitro salisphere formation and in-vivo tumorigenic potential of cells selected by 






the ll ing putative CSC marke  combinations.
ALDH/CD44
Salisphere Formation In Vivo Tumorigenicity
UM-HMC-3A UM-HMC-3B Low-Passage High-Passage
High/High High High High High
High/Low NA NA NA NA
Low/High High High NA NA




High/High Low High NA Low
High/Low Low Intermediate NA Low
Low/High Intermediate Intermediate NA None




High/High Low Low Low High
High/Low Intermediate Low Low Low
Low/High Intermediate High High Low




High/High Intermediate High None NA
High/Low Low NA NA NA
Low/High High Intermediate NA NA




Figure III.4: In vitro salisphere analysis of FACS-sorted mucoepidermoid carcinoma cell 
lines (UM-HMC-3A, UM-HMC- 3B). A.-D. Ultra-low attachment plates were seeded with 2,000 
cells/well (6-well plates), and cells were cultured for seven days to generate primary 
salispheres. Then, salispheres were dissociated into single cell suspensions, seeded in new 
ultra-low attachment plates, and secondary salispheres were counted after additional seven 
days. A. Graph depicting the average number of salispheres per well of cell lines FACS-sorted 
for ALDH/CD44 (n = 4-6). B. Graph depicting the average number of salispheres per well of cell 
lines FACS-sorted for CD10/CD24 expression (n = 5-6). C. Graph depicting the average 
number of salispheres per well of cell lines FACS-sorted for CD44/ CD24 cells (n = 6). D, Graph 
depicting the average number of salispheres per well of cell lines FACS-sorted for CD10/CD44 
sorted cells (n = 5-6). All images were taken at 40X. Statistical analysis was performed using 
one-way ANOVA. Different low case letters indicate statistical difference at p < 0.05.  
 
Cells sorted for CD10/CD24 showed significant differences in the number of 
salispheres. In the UM-HMC-3A cells, the CD10lowCD24low population significantly 
outgrew the other populations. The CD10lowCD24high population also showed 
considerable salisphere formation in this cell line. Interestingly, the UM-HMC-3B cells 
showed an outgrowth of the CD10highCD24high population in secondary salispheres 
(Figure III.4B, Table III.2). UM-HMC-3A cells sorted according to CD44/CD24 marker 
combination also showed significant differences in salisphere formation, specifically in 
the CD44lowCD24low population. In contrast, UM-HMC-3B cells showed growth in the 
CD44lowCD24high population in secondary salispheres (Figure III.4C, Table III.2). Finally, 
UM-HMC-3A and UM-HMC-3B cells were sorted by CD10/CD44. In the UM-HMC-3A 
cells, the CD10lowCD44high population formed the most secondary salispheres. In the 
UM-HMC-3B cells, the only populations that had sufficient numbers to enable us to 
perform this assay were the CD10highCD44high and CD10lowCD44high cells. We observed 
that CD10highCD44high formed significantly more primary salispheres than the 
CD10lowCD44high cells (Figure III.4D, Table III.2). 
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 We observed that the marker combinations tested here showed different patterns 
of salisphere growth. ALDHhighCD44high and ALDHlowCD44high populations showed 
consistent salisphere formation, and therefore this combination was selected for the first 
in vivo studies (see below). The CD10/CD24, CD44/CD24, and CD10/CD44 marker 
combinations showed significant variability in salisphere growth. Nevertheless, these 
marker combinations were also tested in vivo for tumorigenic potential. 
Combination of ALDH activity and CD44 expression selects highly tumorigenic 
cells 
As a critical follow-up to the in vitro studies, putative cancer stem cell markers were 
verified in vivo to ascertain self-renewal and tumorigenic potential. We first decided to 
FACS-sort for ALDH/CD44 and implant these cells in vivo to observe possible 
differences in tumorigenic potential. Because of the extended length of time needed to 
grow low passage cell line-derived tumors, we digested UM-HMC-3A (passage 14) and 
UM-HMC-3B (passage 27) xenograft tumors and then sorted these cells for 
ALDH/CD44. The sorted cells were seeded with primary human endothelial cells into 
biodegradable scaffolds, and transplanted into the SCID mice, as described earlier (38-
40). Either 400 of the ALDHhighCD44high cells, or 4,000 of the ALDHlowCD44low cells (i.e. 
10x more cells), were transplanted into mice and serially passaged in vivo. In the first 
generation xenografts, we observed that only ALDHhighCD44high cells generated tumors 
(Figure III.5A and 5B). Interestingly, ALDHhighCD44high-sorted cells were able to 
generate tumors with similar histology as compared to the tumors generated from the 
unsorted cells (Figure III.5D). We next took the tumors generated with ALDHhighCD44high 




Figure III.5: Tumorigenic potential of low passage mucoepidermoid carcinoma cells 
sorted for ALDH/CD44. A., B. Graphs depicting tumor volume of A. UM-HMC-3A or B. UM-
HMC-3B xenograft cells FACS-sorted for ALDH/CD44. Scaffolds were seeded with either 400 
ALDHhighCD44high or 4,000 ALDHlowCD44low cells and transplanted into the subcutaneous 
space of SCID mice. Existing tumors were retrieved, re-sorted and 400 ALDHhighCD44high or 
4,000 ALDHlowCD44low cells seeded into new scaffolds, and serially passaged in vivo. C. 
Table depicting the number of tumors grown in the ALDHhighCD44high versus 
ALDHlowCD44low populations for each passage performed. D. H&E staining of tumors 
generated with FACS-sorted ALDHhighCD44high and ALDHlowCD44low cells. Images were 
taken at 100X. E. UM-HMC-3A and UM-HMC-3B cells were sorted for ALDHhighCD44high or 
combined ALDHhighCD44low, ALDHlowCD44high, and ALDHlowCD44low (non-CSC 
population). NP-40 lysis buffer was used to prepare whole cell lysates that were resolved using 
PAGE. Membranes were probed using antibodies a 1:1000 dilution against human mTor, p-
mTor, Akt, p-Akt, S6K, p-S6K, p-EGFR; 1:2000 dilution of EGFR, and beta-actin.  
 
ALDHlowCD44low cells into new mice. While the ALDHhighCD44high cells generated 
tumors in 9/20 transplants, ALDHlowCD44low cells generated tumors in only 1/20 
transplants (Figure III.5A and 5B). Finally, we did a third cycle of in vivo passaging of 
the ALDHhighCD44high tumors. Here, only mice transplanted with ALDHhighCD44high cells 
generated tumors (Figure III.5A and  5B). Notably, no secondary tumors were 
generated from the only ALDHlowCD44low tumor that grew in this experiment. Overall, we 
observed 18 tumors generated with 400 ALDHhighCD44high cells, while only one tumor 
was generated when 4,000 ALDHlowCD44low cells were transplanted (Figure III.5C). 
Collectively, these data showed that ALDHhighCD44high cells exhibit enhanced 
tumorigenic potential, when compared with ALDHlowCD44low cells. Notably, the unique 
tumorigenic potential of ALDHhighCD44high cells persisted over multiple in vivo tumor 
passages, suggesting enhanced self-renewal of this sub-population of cells.  
As the ALDHhighCD44high showed elevated tumorigenic potential, we performed 
western blot analysis to determine if UM-HMC-3A and UM-HMC-3B ALDHhighCD44high 
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cells showed activation of the PI3K-Akt pathway important in cancer stem cells function. 
While the levels of EGFR and phosphor-EGFR remained stable between the combined 
ALDHhighCD44low, ALDHlowCD44high, and ALDHlowCD44low populations (non-stem cell) 
and ALDHhighCD44high cells, there was an upregulation of phosphor-mTor and phospho-
S6K in the UM-HMC-3A cells (Figure III.5E). In the UM-HMC-3B cells, we also observed 
an upregulation of p-mTor and p-S6K as well as an upregulation of p-Akt (Figure III.5E). 
Together these results suggest that the PI3K-Akt pathway is upregulated in the 
ALDHhighCD44high compared to the non-stem cell population. 
We next wanted to understand whether these differences in tumorigenic potential 
where reproducible using higher passage cells in independent in vivo experiments. We 
sorted UM-HMC-3B cells (passage 103) for ALDHhighCD44high and ALDHlowCD44low, 
seeded the sorted cells with primary human endothelial cells into biodegradable 
scaffolds, and transplanted them into the SCID mice. Tumors were measured weekly 
and considered palpable once they reached 200 mm3 (Figure III.6A, Table III.2). 
Kaplan-Meyer analysis demonstrated that the tumorigenic potential of ALDHhighCD44high 
cells was higher than the ALDHlowCD44low cells (log-rank test, p=0.025) (Figure III.6B). 
We performed regression analysis to determine the impact of ALDH/CD44 marker 
combination on tumor growth rate. Once tumors had grown to 200 mm3 we performed a 
linear mixed effect model on the tumor size, including the following variables in our 
model of log tumor volume: size of tumor at first palpability; ALDHhighCD44high state; 
time; time by ALDHhighCD44high cell state interaction (Figure III.6C). As expected, the 
volume of the tumor increased proportionally to the size of the initially palpable tumor 




Figure III.6: Tumorigenic potential of high passage mucoepidermoid carcinoma cells 
sorted for ALDH/CD44. A. Graph depicting the volume of tumors generated by the 
transplantation of FACS-sorted UM-HMC-3B cells (ALDHhighC44high or ALDHlowCD44low) in 
immunode cient mice. 5,000 sorted UM-HMC-3B cells (passage 103) and 900,000 endothelial 
(HDMEC) cells were seeded on biodegradable scaffolds and transplanted into the 
subcutaneous space of SCID mice. Tumors were measured weekly and mice were euthanized 
once the tumors reached 700-1,500 mm3. B. Kaplan-Meyer analysis of time to palpability of 
tumors generated with ALDHhighCD44high or ALDHlowCD44low cells. Tumors were 
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considered palpable once they reached 200 mm3. C. Regression analysis of growth after 
palpability (200 mm3) of tumors generated with FACS-sorted ALDHhighCD44high or 
ALDHlowCD44low cells. D. H&E staining of tumors generated with FACS-sorted 
ALDHhighCD44high and ALDHlowCD44low cells. Images were taken at 40X and 100X. E. 
Graph depicting the volume of tumors generated by the transplantation of FACS-sorted UM-
HMC-3B cells (ALDHhighC44high or ALDHhigh) in immunode cient mice. 5,000 sorted UM-
HMC-3B cells (passage 104) and 900,000 endothelial (HDMEC) cells were seeded on 
biodegradable scaffolds and transplanted into the subcutaneous space of SCID mice. Tumors 
were measured weekly and mice were euthanized once the tumors reached 700-1,500 mm3. F. 
Kaplan-Meyer analysis of time to palpability of tumors generated with ALDHhighC44high or 
ALDHhigh cells.  
 
 
tumor growth rate for ALDHhighCD44high tumors compared to ALDHlowCD44low tumors 
(p=0.0042). We plotted the time since first-palpability versus tumor volume. Overlaid on 
this graph are the model-derived growth predictions. To generate the curves for each 
group, we used the mean size at time of first palpability for each group, and the 
appropriate estimated coefficients and interactions from the model. Tumors generated 
with ALDHhighCD44high cells showed a distinctly different morphology from the tumors 
generated with ALDHlowCD44low cells (Figure III.6D). Both are characterized by large 
solid areas, but tumors generated with ALDHhighCD44high cells showed more 
intermediate-like cells, with spindle shape, oval nuclei and highly anaplastic areas. In 
contrast, the tumors generated with ALDHlowCD44low cells showed a more monotonous 
morphology with round cells exhibiting round nuclei and clusters of epidermoid-like cells 
with eosinophilic cytoplasm. Interestingly, anaplastic cells were more rare in the tumors 
generated with ALDHlowCD44low cells. 
As the majority of high passage UM-HMC-3B cells stain highly for CD44, we next 
questioned whether ALDH could be used as a single marker for this aggressive cancer 
stem cell phenotype. To investigate this, we took high passage (passage 104) UM-
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HMC-3B cells and sorted for ALDHhighCD44high and ALDHhigh then transplanted these 
cells with human endothelial cells on biodegradable scaffolds into the SCID mice. In 
these studies, we were able to generate tumors in 4 (out of 10) scaffolds seeded with 
ALDHhighCD44high cells while no tumors were generated in the ALDHhigh cells (Figure 
III.6E). Our Kaplan-Meyer analysis shows that the tumorigenic potential of 
ALDHhighCD44high cells is greater than the ALDHhigh cells (log-rank test, p-0.025) (Figure 
III.6F). These data suggest that ALDH by itself does not enrich for an aggressive cancer 
stem cell phenotype in salivary gland mucoepidermoid carcinoma.  
We next performed FACS analysis of the ALDH/CD44 sorted xenograft tumors 
over multiple passages to verify if ALDHhighCD44high cells were able to differentiate. We 
observed that tumors generated with pure populations of ALDHhighCD44high cells were 
able to continuously repopulate the other ALDH/CD44 sub-populations and that the 
fraction of the different sub-populations was consistent with the original unsorted 
xenograft tumors (Figure III.7A and 7B). We also performed immunofluorescence 
staining of the original unsorted tumors and compared with the 1st passage 
ALDHhighCD44high-sorted tumors. We found once again that the ALDHhighCD44high 
generated tumors were able to repopulate the remaining three sub-populations (Figure 
III.7C). We also performed immunofluorescence staining in tumors generated from our 
second independent experiment with FACS-sorted ALDHhighCD44high cells or 
ALDHlowCD44low cells to determine the ability of these relatively pure sub-populations of 
cells to regenerate complex tumors once transplanted in mice. We found that CD44 




Figure III.7. Characterization of xenograft tumors generated with cells sorted for 
ALDH/CD44. A. Graph depicting the percentage of ALDH/CD44 cells in tumors generated with 
FACS-sorted UM-HMC-3A (passage 14) over three in vivo passages. B. Graph depicting the 
percentage of ALDH/CD44 staining cells in tumors generated with FACS-sorted UM-HMC-3B 
(passage 27) over two in vivo passages. C. Immuno uorescence staining of tumors generated 
from the original unsorted UM-HMC-3A (passage 14) and UM-HMC-3B (passage 27) xenograft 
cells compared to tumors generated from 400 ALDHhighCD44high cells sorted from the original 
xenografts. CD44 is stained in red while ALDH-1 is stained in green. D. Immuno uorescence 
staining of tumors generated with FACS-sorted ALDHhighCD44high or ALDHlowCD44low cells. 
CD44 is stained in red while ALDH-1 is stained in green. E. Graph depicting the percentage of 
ALDHhigh cells in tumors generated with cells FACS-sorted for ALDHhighCD44high or 
ALDHlowCD44low as determined by flow cytometry with Aldefluor.  
 
generated with ALDHlowCD44low cells. The pattern of ALDH expression was different. 
Tumors generated with FACS-sorted ALDHhighCD44high showed more ALDH1 staining 
than tumors generated with ALDHlowCD44low cells (Figure III.7D and 7E). Interestingly, 
the presence of cells that are positive for the stem cell marker ALDH1 in tumors 
generated with FACS-sorted ALDHlowCD44low cells suggests that perhaps some of 
these cells are capable of dedifferentiation. Nevertheless, the percentage of ALDHhigh 
cells was lower in the tumors generated with ALDHlowCD44low cells when compared to 
tumors generated with ALDHhighCD44high cells (Figure III.7E).  
Tumorigenic potential of mucoepidermoid carcinoma cells FACS-sorted for 
CD10/CD24, CD44/CD24, CD10/CD44 
In addition to the work performed with ALDH/CD44, we have also performed extensive 
testing of three additional putative stem cell marker combinations (CD10/CD24, 
CD44/CD24, CD10/CD44) to determine if these markers could enrich for cancer stem 
cells in vivo. We transplanted UM-HMC-3B FACS-sorted cells (CD10/CD24 or 
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CD10/CD44) into mice, as described above. We observed only two tumors generated 




Figure III.8. In-Vivo tumorigenicity of low passage CD44/CD24 sorted cells. A. Tumor 
growth chart of CD10/CD24 sorted cells. Scaffolds were seated with 2,000 CD10/CD24 sorted 
cells and 900,000 HDMEC cells. B. Tumor growth chart of CD10/CD44 sorted cells. Scaffolds 
were seated with either 500 CD10highCD44high cells or 5,000 CD10lowCD44low cells along with 
900,000 HDMEC cells. C. Tumor growth chart of tumors generated from UM-HMC-3B (passage 
27) 9th generation xenograft cells that were sorted according to the expression of CD44/CD24. 
D. Graph depicting the time to palpability of CD44/CD24 sorted tumors. Tumors were 
considered palpable once they reached 200 mm3. E. H&E staining of sections taken from UM-
HMC-3B (passage 27) 9th generation xenograft CD44/CD24 sorted cells. F. Flow cytometry 
analysis of UM-HMC-3B (passage 27) 9th generation xenograft CD44/CD24 sorted tumors. 
Primary tumors were digested and stained for CD44 and CD24.  
 
 
group and 1 (out of 6) in the CD10highCD24low group (Figure III.8A, Table III.2). Further, 
only two CD10lowCD44low tumors were formed when CD10/CD44-sorted cells were 
transplanted (Figure III.8B, Table III.2). These data demonstrated that these two marker 
combinations involving CD10 do not select for uniquely tumorigenic cancer stem cells.  
We next performed experiments with the CD44/CD24 marker combination using 
cells that were sorted from ongoing UM-HMC-3B xenograft tumors. Because different 
sub-populations of CD44/CD24 are used to isolate cancer stem cells in different cancer 
types, we FACS-sorted all four sub-populations and implanted them as described 
above. Four (out of 6) CD44lowCD24high transplants grew tumors, whereas only 1 (out of 
6) mouse transplanted with CD44highCD24high or CD44highCD24low, and 2 (out of 6) mice 
developed tumors when transplanted with CD44lowCD24low cells (Figure III.8C; Figure 
III.9F, Table III.2). While these initial results suggested that CD44lowCD24high sub-
populations were more tumorigenic, we did not observe significant differences in the 
time to palpability upon Kaplan-Meyer analyses (Figure III.8D), nor did we observe that 
a certain sub-population of cells generated tumors with a particularly aggressive 
histology (Figure III.8E). We then digested the tumors and re-stained for CD44/CD24 to 
analyze how the sub-populations of cells redistributed during growth in mouse. In the 
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original xenograft tumors used to collect the cells for this experiment, the 
CD44lowCD24low sub-population was the lowest (Figure III.8F). In contrast, in the tumors 
generated from FACS-sorted cells, we observed an overall trend for high fractions of 
CD44lowCD24low cells irrespective of what was the sub-population used to generate the 
tumors.  
These surprising results led us to repeat this experiment using cells sorted 
directly from the UM-HMC-3B cell line. In this experiment, the four sub-populations of 
cells sorted for CD44/CD24 were able to grow tumors (Figure III.9A, 9F, Table III.2), but 
no difference was seen in the time to palpability (p=0.403) among these four 
experimental conditions (Figure III.9B). Nevertheless, we did observe significant 
differences in tissue morphology. The CD44lowCD24low and CD44highCD24high tumors 
grew more aggressively and showed a solid morphology with large areas of anaplasia. 
In contrast, CD44highCD24low and CD44lowCD24high cells generated tumors exhibiting a 
less aggressive, mucous cell phenotype (Figure III.9C). We again performed regression 
analyses to determine if differences in tumor growth rates existed based on the different 
sub-populations of cells that were used to generate these tumors. Based on the 
significant histologic differences that we observed between four combinations of CD24 
and CD44 cells, we included the following variables in our model of log tumor volume: 
size of tumor at first palpability; CD24 state; CD44 state; CD24 by time interaction; 
CD44 by time interaction; and CD24 by CD44 by time interaction. The rate of tumor 
growth was significantly less in CD24-positive (p=0.0003), and CD44-positive 




Figure III.9. Tumorigenic potential of mucoepidermoid carcinoma cells sorted for 
CD44/CD24. A. In vivo transplantation of 5,000 UM-HMC-3B (passage 103) FACS-sorted cells 
(CD44highCD24high, CD44highCD24low, CD44lowCD24high, or CD44lowCD24low) with 
900,000 endothelial (HDMEC) cells seeded on biodegradable scaffolds and transplanted into 
the subcutaneous space of SCID mice. B. Kaplan-Meyer analysis of time to palpability of tumors 
generated with cell sorted for CD44/CD24. Tumors were considered palpable once they 
reached 200 mm3. C. H&E staining of tumors generated by the transplantation of UM-HMC-3B 
cells sorted for CD44/CD24. Images were taken at 40X and 100X. D. Regression analysis of 
growth after palpability (200 mm3) of tumors generated with cells FACS-sorted for CD44 and 
CD24. E. Graph depicting the percentage of ALDHhigh cells in tumors generated with cells 
FACS-sorted for CD44/CD24. F. Table depicting the number of tumors formed in each 
CD44/CD24 sorted sup-population in both the UM-HMC-3B cell line and the UM- HMC-3B low 
passage cell line xenograft model.  
 
interaction effect, which yielded a higher rate of growth for CD44highCD24high tumors 
(p<0.0001). We again plotted the time since first-palpability versus tumor volume 
(Figure III.9D). To further investigate the absence of differences in tumor initiating 
potential (as determined by time to palpability) among the cells sorted for CD44/CD24, 
we analyzed whether any sub-population was enriched for ALDH. Interestingly, no 
significant difference in the fraction of ALDHhigh cells was observed when we compared 
tumors generated with FACS-sorted CD44highCD24high, CD44highCD24low, 
CD44lowCD24high, or CD44lowCD24low cells (Figure III.9E). Collectively, these data 
indicate that the CD44/CD24 marker combination does not enable consistent 
identification of a unique population of highly tumorigenic cells in salivary gland 
mucoepidermoid carcinomas.   
Discussion 
 
Poor survival of patients with advanced stage salivary gland mucoepidermoid 
carcinomas demand better understanding of the pathobiology of these tumors and the 
development of new, mechanism-based therapies. Research in other cancer types 
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suggests that cancer stem cells play an important role in resistance to therapy and 
tumor relapse (18, 41-44). Much has been done therapeutically to target the self-
renewal pathways important in cancer stem cell function. Several groups have therapies 
to inhibit the Notch, Wnt, and Hedgehog pathways (46). In addition, Her2-specific 
antibodies have been used to target breast cancer stem cells while IL-6 antibodies have 
been used in head and neck squamous cell carcinomas (47, 27). The relentless growth 
of mucoepidermoid carcinomas, compounded with resistance to every therapy that was 
attempted this far, is a major clinical challenge that might be correlated with the function 
of cancer stem cells. However, whether or not cancer stem cells play a role in the 
pathobiology of salivary mucoepidermoid carcinomas has not been investigated due a 
lack of adequate research models (i.e. cell lines, xenograft models) and unavailability of 
markers that enable the identification of sub-populations of cells with unique tumorigenic 
potential. Previously, we generated and characterized a number of cells lines and 
xenograft models of salivary gland mucoepidermoid carcinoma (38).  
By co-transplanting sorted human mucoepidermoid carcinoma cells with primary 
human microvascular endothelial cells in biodegradable scaffolds, we were able to 
generate xenograft tumors vascularized with human blood vessels, as previously 
described (38-40). We have showed that this experimental approach enables the 
crosstalk between tumor cells and endothelial cells of the same species, which has a 
demonstrable impact to both tumor growth as well as response to therapy (48). Here, 
we demonstrated that the combination of ALDH activity and CD44 expression enables 
the identification of highly tumorigenic cells in salivary gland mucoepidermoid 
carcinoma. While primary cells are a preferred model to study, we are limited by the 
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rarity by these tumors, as well as the difficulty and length of time needed to grow 
primary cells in vitro and in vivo. However, the results presented here, together with the 
recent characterization of cell lines and xenograft models of mucoepidermoid carcinoma 
[38], will enable studies focused on the understanding of the mechanisms underlying 
the role of cancer stem cells in resistance to therapy, and the development of strategies 
to overcome this resistance.  
While the salisphere assay is a useful method to screen for cancer stem cells 
markers in-vitro, the ability of these markers to enrich for cells that are able to self-
renew and are multipotent must be verified in-vivo. Most of these in vivo experiments 
lasted around 200 days, and some of them lasted more than one year (e.g. sequential 
in vivo passaging of sorted cells). The extended time necessary to achieve tumor 
palpability, and the relatively slow tumor growth after palpability consumed significant 
resources and delayed the progression of this work. However, we believe that the 
results observed in these preclinical experiments reflect the normal behavior of human 
mucoepidermoid carcinomas, which are slow growing, albeit relentless, tumors.  
A series of complementary independent in vivo studies demonstrated that the 
ALDH/CD44 marker combination enriches for cancer stem cells in mucoepidermoid 
carcinomas. While ALDH can be used as an independent marker for cancer stem cells 
in other cancer types, we have demonstrated that a two-marker combination of ALDH 
and CD44 is necessary to enrich for this aggressive cancer stem cell phenotype (10). In 
contrast, cells sorted for CD10/CD24 or CD10/CD44 showed differences in salisphere 
formation, but poor ability to generate tumors in vivo. We concluded that these marker 
combinations do not enrich for cancer stem cells, at least in the models studied here. 
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We also concluded that the CD44/CD24 combination does not enrich for cancer stem 
cells. In this case, we observed differences in salisphere formation and tumor growth. 
However, the sub-populations of interest were not consistent from experiment to 
experiment. Interestingly, several tumors generated in these experiments were very 
aggressive, showing solid morphology with large areas of anaplasia. Paradoxically, 
these aggressive tumors were observed primarily when cells sorted for 
CD44highCD24high or CD44lowCD24low were transplanted. A mechanistic understanding of 
these puzzling findings is beyond the scope of this manuscript. However, these data 
reinforced the concept that the CD44/CD24 combination is likely not a viable marker 
combination for mucoepidermoid carcinoma cancer stem cells. 
The PI3K-Akt signaling pathway has been found to be important in the 
maintenance of cancer stem cells (49, 50). Interestingly, the EGFR and HER2-Akt-
mTOR pathways are activated in salivary gland cancer (51). We observed that 
ALDHhighCD44high cells potently express P-mTor and p-S6K, when compared to control 
cells. Considering the promising results of clinical and preclinical studies with rapamycin 
and rapalogs, the observation that mucoepidermoid carcinoma stem cells present high 
constitutive activity of the mTor pathway potentially has considerable translational 
impact. Indeed, these results might lead to a new therapeutic target for this malignancy 
that will be explored in future studies by our laboratory. 
While we have concluded from our studies that ALDHhighCD44high cells 
demonstrate CSC properties, further research must be done to verify if both ALDH and 
CD44 play an active role in the maintenance of this stem cell phenotype. ALDH1 has 
been widely used as a cancer stem cells marker due to its role in normal stem cells 
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function. However, whether or not it plays an active role in cancer stem cell 
maintenance in mucoepidermoid carcinoma is unclear (23). Further, little is known 
about the role of CD44 in the progression of mucoepidermoid carcinomas. CD44 has 
been shown to play an important role in resistance to radiation and chemotherapy and 
may play a role in tumor recurrence of head and neck squamous cell carcinomas (52). 
The protein is encoded by one gene, but due to post-transcriptional modifications and 
alternative splicing, many variants of CD44 exist (52). Studies have implicated CD44v6 
to be more effective in isolating CSC, however, work in HNSCC showed similar levels of 
expression between CD44s and CD44v6 suggesting that this effect may be specific to 
various cancer types (53-57). The antibody that was used in our studies was not 
specific to the CD44v6 splice variant. It is possible to using antibodies specific to this 
variant may lead to a further enrichment of the cancer stem cells in mucoepidermoid 
carcinomas, but this hypothesis was not tested here. 
Collectively, this work demonstrates that salivary gland mucoepidermoid 
carcinomas exhibit a small sub-population of cells with uniquely high tumorigenic 
potential. These cells can be identified by high ALDH activity and CD44 expression. 
Considering the role of cancer stem cells in tumor recurrence and resistance to therapy 
in other glandular cancers (e.g. breast, pancreatic), it is tempting to predict that these 
cells may also play a functional role in the relentless growth and resistance to therapy 
typically exhibited by human mucoepidermoid carcinomas. These results suggest that 
patients with mucoepidermoid carcinoma might benefit from the targeted ablation of this 
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A rare population of cancer stem cells, characterized by increased tumorigenic potential 
and multipotency, has been described in several cancer types. This tumorigenic 
population of cells is defined by ALDHhighCD44high in salivary gland mucoepidermoid 
carcinoma. While frequently mutated in many cancer types, wild type p53 plays in 
important role in the induction of apoptosis under mutagenic stress as well as stem cell 
quiescence and differentiation. MI-773, a small molecule inhibitor, functions to prevent 
MDM2 inhibition of p53 thereby allowing p53 to induce apoptosis and differentiation 
within the cell. The purpose of our research is to therapeutically target cancer stem cells 
thereby sensitizing the tumors to chemotherapy treatments. In-vitro treatment of 
mucoepidermoid carcinoma cells UM-HMC-1, UM-HMC-3A, and UM-HMC-3B with MI-
773 was shown to drastically increase expression of p53, MDM2, and p21. We also 
observed an induction of G1 cell cycle arrest as well as apoptosis. Interestingly, a 
marked decrease in expression of the marker of self-renewal, Bmi-1, was seen in stem 
cells treated with MI-773. In correlation, treatment with low doses (1 µm) of MI-773 
significantly reduced the proportion of ALDHhighCD44high cells. Short-term in-vivo 
treatment of MI-773 in cell line-derived xenografts also induced cell cycle arrest and 
apoptosis. Importantly, a significant reduction in ALDHhighCD44high cell population and 
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Bmi-1 expression was also seen in the xenografts. Collectively, our data suggests that 
p53 is an important regulator of stem cell differentiation in mucoepidermoid carcinomas 
and that targeting of MDM2 effectively reduces the cancer stem cell population in these 
tumors.  
Introduction 
 Salivary gland mucoepidermoid carcinomas (MEC) are the most common 
salivary malignancy, accounting for 30-35% of all malignant salivary gland tumors (1-8). 
Patients diagnosed with mucoepidermoid carcinomas are treated using surgical 
resection and radiation therapies (9). While this treatment is often sufficient for patients 
with low to intermediate-grade tumors, patients with high-grade tumors often display 
recurrent disease years after initial treatment which is, in most cases, fatal (10). 
Importantly, mucoepidermoid carcinomas are chemotherapy-resistant leaving no other 
treatment options available for these patients with advanced, recurrent disease (11). 
Improved understanding of pathobiology driving MEC growth is essential for the 
identification of effective therapies. 
 A subpopulation of cells, termed cancer stem cells (CSC), is uniquely 
tumorigenic and capable of multipotency and self-renewal. Cancer stem cells are 
essential for both initiating and maintaining the growth of many cancer types (12). 
Importantly, cancer stem cells are resistance to conventional chemotherapies and 
radiation treatments due to the suppressed rate of growth and the presence of 
transporter proteins as well as micro-environmental influences (13-15). Survival of these 
cells after treatment allows for tumor regrowth and recurrence. Previous work done in 
our laboratory identified cancer stem cells in salivary gland mucoepidermoid carcinomas 
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(16). MEC cells sorted for ALDHhighCD44high are highly tumorigenic in in-vivo models 
compared to the non-CSC population of cells. Importantly, ALDHhighCD44high cells are 
capable of self-renewal and multipotency. Selective targeting and ablation of 
ALDHhighCD44high cells is critical towards achieving total disease remission in patients 
with mucoepidermoid carcinoma.  
 p53 is a transcription factor that plays an essential role in many cellular functions. 
Among the most critical are regulating the cell cycle and senescence as well as the 
induction of apoptosis upon the damage to the genome (17-19). Importantly, p53 plays 
a key role in adult and embryonic stem cell differentiation.  In normal differentiated cells, 
deletion or repression of p53 function lead to greater efficiency in dedifferentiating into 
induced pluripotent stem cells (20-24). In the context of cancer, research has shown 
that loss of p53 also led to the expansion of malignant reprogrammed progenitor cells in 
cancer (25). Mouse double minute 2, MDM2, is a key regulator of p53. MDM2 binds the 
transactivation domain and ubiquitinates p53, signaling it for degradation in the 
proteasome (26). MDM2 serves as an oncogene and is overexpressed in many cancers 
as it prohibits p53 from inducing apoptosis upon malignant expansion.  
 Many MDM2/p53 small molecule inhibitors have been generated that interrupt 
MDM2 binding to p53. One molecule in particular, MI-773, has been shown to have 
significantly greater specificity and affinity to MDM2 when compared to p53 binding, a 
previously developed MDM2 inhibitor, Nutlin-3a, binding, and previous analog MI-219 
binding (27). Importantly, MI-773 was able to activate p53 activity and induce apoptosis 
in cancer cells at a much greater efficiency when compared to Nutlin-3a (27). Notably, 
this therapeutic effect was seen in cell lines with both wild-type and mutated p53 (28). 
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 While much work has been done to determine the therapeutic effect of MI-773 in 
inducing apoptosis and diminishing tumor volume, no studies have been performed to 
characterize MI-773 efficacy in salivary gland mucoepidermoid carcinoma or it’s impact 
on stem cell function. Hence, the focus of our study is to investigate the therapeutic 
effect of MI-773 on cancer stem cells in salivary gland mucoepidermoid carcinomas. 
Our findings suggest that MDM2/p53 binding inhibition is not only effective in inducing 
apoptosis and cell cycle arrest in mucoepidermoid carcinoma cells, but is also a 
powerful agent in reducing the ALDHhighCD44high cancer stem cell population. Together, 
these findings unveil a unique therapy for the treatment of mucoepidermoid carcinoma 
cancer stem cells. 
 
Materials and Methods 
 
Cell Culture 
HMC cells, previously characterized in our laboratory, (UM-HMC-1, UM-HMC-3A, and 
UM-HMC3B) cells were cultured using DMEM (Gibco) enriched with 10% FBS (Gibco), 
1% 200nM L-Glutamine (Gibco), 1% Penicillin and Streptomycin (Gibco), 20 ng/mL 
epidermal growth factor (Sigma), 400 ng/mL hydrocortisone (Sigma), 5 ug/mL insulin 
(Sigma #I-1882). Cells were trypsinized using 0.05% trypsin (Gibco). Human endothelial 
cells were grown using EBM media (Lonza) (29).   
Immunohistochemistry and Immunofluorescence Staining 
Tissue section slides for immunohistochemistry and immunofluorescence staining were 
de-paraffinized using xylene and ethanol washes. Following de-paraffinization, sections 
were incubated with 0.1% Triton-x100 for 10 minutes, 3% hydrogen peroxide for 10 
minutes, and Background Sniper (Biocare Medical) for 10-30 minutes. 
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Immunohistochemistry slides were incubated with anti-p53 (Santa Cruz) and anti-MDM2 
(Santa Cruz) overnight at 4C. Following incubation with primary antibody, sections were 
washed two times for 10 minutes and incubated with MACHI 3 Probe (Biocare Medical) 
for 20 minutes. After two 10 minute washes, sections were incubated with MACHI 3 
HRP Polymer for 20 minutes and again washed two times for 10 minutes. Sections 
were then incubated with DAB for 3 minutes and quenched in water. Sections were 
finally incubated with hematoxycin for 45 seconds, dehydrated in ethanol and mounted. 
Immunofluorescence sections were incubated with anti-ALDH (Abcam) overnight at 
room temperature. The following day, sections were washed for three 5-minute washes 
and incubated with Alexafluor 488 (Anti-Rabbit, Invitrogen). After three 5 minute 
washes, sections were incubated with 3% hydrogen peroxide for 30 minutes followed by 
1 hour incubation with anti-CD44 (Thermo Scientific) and a 20 minute incubation with 
Aliexafluor 594 (Anti-Mouse, Invitrogen). Slides were imaged with DAPI. TUNEL 
staining was performed using TUNEL staining kit (Roche) and a DAPI stain. Seven 
200X image fields were taken per section and the pixel density was quantitated using 
ImageJ software.  
Western Blot 
HMC cell and tissue section lysates were digested using NP-40. Lysates were run using 
PAGE gels and probed using anti-p53 (SantaCruz), anti-MDM2 (SantaCruz), anti-p21 
(Cell Signaling), Bmi-1 (Cell Signaling), anti Cyclin-A (Santa Cruz), anti-Cyclin-D (Santa 
Cruz), anti-Cyclin-E (Cell Signalling), anti-CDK2 (Santa Cruz), anti-CDK4 (Santa Cruz), 
anti-CDK6 (Santa Cruz), and anti-Bcl-xL (BD Transduction).  
PCR and Sequencing 
	 87	
RNA was isolated from sorted and unsorted HMC cells and reverse transcribed. cDNA 
was PCR amplified using sense and anti-sense primers targeting full length p53 and 
residues 54-716, 460-1179, and 876-1412. PCR products were run on a 1.5% agarose 
gel. Fragments were excised and purified for Sanger sequencing.  
WST-1 
HMC cells were plated at 500 cells per well in a 96-well plate and allowed to attached 
overnight. MI-773 was solubilized in DMSO and added at varying concentrations to the 
cells using DMSO only treatments as a control. Cells were incubated with the drug for 
24, 48, or 72 hours. 10uL of WST-1 reagent (Roche) was added to the cells and 
incubated at 37C for 4 hours. Plates were then analyzed using a plate reader.  
Flow Cytometry 
For ALDH/CD44 staining, cells were trypsinized and alloquoted 2 million cells per tube. 
10uL of Aldefluor (Caymen Chemicals) was added to each tube and 10 uL of DEAB was 
added to the DEAB control tube. Cells were incubated for 40 minutes at 37C then 
stained with 5uL of CD44 (BD) for 30 minutes at 4C. For propidium iodine staining, cells 
were fixed in 70% ethanol overnight at -20C and stained in 1mg/mL propidium iodide 
(BD), 1% sodium citrate, 1mg/mL RNaseA, 10% Triton X-100 for 20 minutes. For 
Annexin V staining, cells were washed in PBS then suspendeded in 1X Binding Buffer 
(BD). 5uL of Annexin V (APC, BD) was added to 100,000 cells and incubated for 20 
minutes at room temperature. In all flow cytometry experiments, 7AAD was used as a 
live/dead control (BD).   
In-Vivo Implantation 
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UM-HMC-3A, UM-HMC-3B, and HDMEC cells were trypsinized and counted. 600,000 
UM-HMC-3A or UM-HMC-3B cells were seeded with 400,000 HDMEC cells in Matrigel 
on biodegradable scaffolds as previously described (30). Scaffolds were implanted 
subcutaneously on the dorsal section of CB17 SCID mice (Charles River). Scaffolds 
were measured weekly until the tumors reached an average volume of 500mm3. MI-773 
was diluted in poly-ethylene glycol and vitamin E. Mice were treated with 200mg/kg, 
100mg/kg, or 50mg/kg for 6 days by gavage. Following the 6 days of treatment, mice 
were euthanized and the tumors removed. Once the tumors were removed, the tissue 
was digested using Tumor Dissociation Kit (Miltenyi Biotec #130-095-929) and the 
gentleMACS Dissociator (#130-093-235). Single cell tumor tissue suspensions stained 




MDM2 and p53 expression in MEC patient specimens and HMC cell lines 
To investigate the expression of MDM2 and p53 in MEC patient samples, we 
stained two MEC patient tissue sections and observed robust MDM2 expression while 
little p53 expression was seen (Figure IV.1A). We next performed western blot analysis 
to determine MDM2 and p53 expression in HMC cell lines generated in our lab (29). 
Both UM-HMC-1 and UM-HMC-3A cell lines showed strong MDM2 expression and 
lower p53 expression (Figure IV.1B). Interestingly, we noticed an opposite trend in UM-
HMC-3B cells, which showed minimal MDM2 expression and elevated p53 expression 
(Figure IV.1B). We next compared MDM2 and p53 expression in ALDHhighCD44high 




Figure IV.1. MDM2 and p53 expression in MEC patient specimens and HMC cell lines. A, 
Representative images of immunohistochemistry staining for MDM2 and p53 in two MEC patient 
tissue samples. Images were taken at 200X. B, Western blot analysis of p53 and MDM2 
expression in UM-HMC-1, UM-HMC-3A, and UM-HMC-3B cells. C, Western blot analysis of p53 
and MDM2 expression in UM-HMC-1, UM-HMC-3A, and UM-HMC-3B cells FACS sorted for 
both the ALDHhighCD44high cancer stem cell population and the remaining cells that were not 
ALDHhighCD44high (i.e. non-cancer stem cells). D, PCR analysis of p53 RNA levels in UM-HMC-
1, UM-HMC-2, UM-HMC-3A, UM-HMC-3B, UM-HMC-5, and a control mucoadeno carcinoma 
sample. E, PCR analysis of p53 RNA expression for both full length p53 as well as primers 
targeting nucleotides 52-716 (Primer #1), nucleotides 460-1179 (Primer #2), and 876-1412 
(Primer #3) of the p53 coding region. RNA was extracted from UM-HMC-3A and UM-HMC-3B 
cells FACS sorted for both the ALDHhighCD44high cancer stem cells population and the non-
ALDHhighCD44high (i.e. non-cancer stem cell) cell population. 
 
observed in UM-HMC-1 and UM-HMC-3A CSC versus non-CSC cells (Figure IV.1C). 
Interestingly, a higher expression of MDM2 was seen in UM-HMC-3B CSC cells 
compared to the non-CSC population suggesting that MDM2 may be differentially 
regulated in the cancer stem cells (Figure IV.1C). Expression of p53 remained 
consistent between CSC and non-CSC in UM-HMC-3B cells (Figure IV.1C).  
To investigate the mRNA expression of p53 in HMC cells, we used PCR primers 
targeting the full-length p53 gene as well as three primers targeting different areas of 
the p53 gene. As PCR amplification of longer genes can generated false mutations, we 
used three primers that targeted three smaller areas of the p53 genes. Primer #1 
targeted residues 54-716 while primers #2 and #3 targeted residues 460-1179, and 
876-1412 respectively. PCR analysis was performed on UM-HMC-1, UM-HMC-2, UM-
HMC-3A, UM-HMC-3B, UM-HMC-5, and mucoadenocarcinoma cell line cDNA (Figure 
IV.1D). Similar mRNA expression of p53 was seen between the HMC cell lines. We next 
sorted UM-HMC-1 (data not shown), UM-HMC-3A, and UM-HMC-3B cells for the 
ALDHhighCD44high cells and non-CSC population and ran PCR analysis on cDNA 
generated from the cells. In our analysis, we used both full-length primers as well as the  
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B.  UM-HMC-1 
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Figure IV.2. p53 sequence in HMC cells. A, Table depicting the p53 mutations in UM-HMC-1, 
UM-HMC-3A, and UM-HMC-3B cells. B, p53 sequence in UM-HMC-1 cells. Three PCR 
products from nucleotides 54-716, 460-1179, 876-1412 were purified and sent for Sanger 
sequencing. Mutations are highlighted in red. C, p53 sequence in UM-HMC-3A cells. Three 
PCR products from nucleotides 54-716, 460-1179, 876-1412 were purified and sent for Sanger 
sequencing. Mutations are highlighted in red. D, p53 sequence in UM-HMC-3B cells. Three 
PCR products from nucleotides 54-716, 460-1179, 876-1412 were purified and submitted for 
Sanger sequencing. Mutations are highlighted in red. 
 
three primers. Similar levels of p53 mRNA was observed between the CSC and non-
CSC populations. We next Sanger sequenced the PCR products from the three primer 
set in UM-HMC-1, UM-HMC-3A, and UM-HMC-3B cell lines and found a A278P 
mutation in UM-HMC-1, UM-HMC-3A, and UM-HMC-3B cells as well as a V157F 
mutation in UM-HMC-3A and UM-HMC-3B cells (Figure IV.2A-D).  
Together these results indicate that our HMC cells express both p53 and MDM2 
in both the cancer stem cell and the non-cancer stem cell populations suggesting that 
MI-773 could be a potential therapeutic agent for targeting the MEC cancer cells and a 
possible agent for targeting CSC in mucoepidermoid carcinoma.  
Effect of MDM2/p53 binding inhibition by MI-773 on the ALDHhighCD44high 
population in HMC cells 
To directly test the effectiveness of MI-773 treatment on the cancer stem cells in 
MEC, we treated UM-HMC-1 cells with 1uM MI-773 for 48, 72, and 96 hours and 
performed FACS analysis for the cells for ALDHhighCD44high cells. At 48, 72, and 96 
hours time points, we observed a dramatic decrease in the ALDHhighCD44high cancer 
stem cell population (Figure IV.3A). To determine whether this decrease was due to 
selective apoptosis of the CSC population or differentiation into a non-CSC cell type, we 
performed a water-soluble tetrazolium-1 (WST-1 analysis. After 72 hour treatment of 
ALDHhighCD44high sorted cells and non-CSC cells with varying concentration of MI-773,  
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Figure IV.3. Effect of MDM2/p53 binding inhibition by MI-773 on the ALDHhighCD44high 
population in HMC cells. A, FACS analysis of UM-HMC-1 cells after 48, 72, and 96-hour 
treatments with 1uM MI-773. Cells were plated at 500,000 cells per flask and treated with 1uM 
MI-773. After the 48, 72, and 96-hour time points, the cells were detached and analyzed for the 
ALDHhighCD44high cancer stem cells population. B, WST-1 analysis of UM-HMC-1 cells FACS 
sorted for the ALDHhighCD44high cancer stem cells and the non-ALDHhighCD44high cells 
population. After sorting, cells were plated at 500 cells per well in a 96 well tissue culture plate. 
Once seated, a concentration gradient (0.1uM-100uM) of MI-773 was added and cells were 
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exposed for 72 hours. Following the 72 hours treatment, 10uL of WST-1 reagent was added for 
4 hours after which the plates were analyzed. C, FACS analysis of UM-HMC-3A cells after 48, 
72, and 96-hour treatments with 1uM MI-773. Cells were plated at 500,000 cells per flask and 
treated with 1uM MI-773. After the 48, 72, and 96-hour time points, the cells were detached and 
analyzed for the ALDHhighCD44high marker combination. D, WST-1 analysis of UM-HMC-3A cells 
FACS sorted for the ALDHhighCD44high cancer stem cells and the non-ALDHhighCD44high cells 
population. After sorting, cells were plated at 500 cells per well in a 96 well tissue culture plate. 
Once seated, a concentration gradient (0.1uM-100uM) of MI-773 was added and cells were 
exposed for 72 hours. Following the 72 hours treatment, 10uL of WST-1 reagent was added for 
4 hours and after which the plates were analyzed. E, FACS analysis of UM-HMC-3B cells after 
48, 72, and 96-hour treatments with 1uM MI-773. Cells were plated at 500,000 cells per flask 
and treated with 1uM MI-773. After the 48, 72, and 96-hour time points, the cells were detached 
and analyzed for the ALDHhighCD44high marker combination. F, WST-1 analysis of UM-HMC-3B 
cells FACS sorted for the ALDHhighCD44high cancer stem cells and the non-ALDHhighCD44high 
cells population. After sorting, cells were plated at 500 cells per well in a 96 well tissue culture 
plate. Once seated, a concentration gradient (0.1uM-100uM) of MI-773 was added and cells 
were exposed for 72 hours. Following the 72 hours treatment, 10uL of WST-1 reagent was 
added for 4 hours and after which the plates were analyzed. 
 
we saw little difference in IC50 values for the CSC versus non-CSC population (CSC: 
8.5uM, Non-CSC: 6.8uM) suggesting that MI-773 induces differentiation of the CSC 
population rather then preferentially affecting the CSC cell number (Figure IV.3B). We 
next performed this analysis in UM-HMC-3A cells and again saw a dramatic decrease in 
ALDHhighCD44high cells, particularly after 72 and 96 hours of treatment (Figure 
IV.3C).Again, we saw little difference in the IC50 values of the CSC versus non-CSC 
population (CSC: 6.0uM, Non-CSC: 2.4uM) suggesting again that MI-773 induces 
differentiation of the ALDHhighCD44high cells (Figure IV.3D). Finally, we again repeated 
this analysis in UM-HMC-3B cells and again saw a dramatic decrease in the CSC 
population after 48, 72, and 96 hours of treatment and little difference in IC50 values 
(CSC: 84.5uM, Non-CSC: 78.4uM) (Figure IV.3E and 3F). Interestingly, both the CSC 
and non-CSC UM-HMC-3B cells showed resistance to MI-773 treatments as indicated 
by the high IC50 values, however, the lack of difference between the IC50 values again 
suggests that the reduction in ALDHhighCD44high cells is due to differentiation rather then 
apoptosis. 
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Together our results suggest that MI-773 is a potent and effective agent in 
reducing the ALDHhighCD44high cancer stem cell population in HMC cells. Our data also 
suggests that this reduction in CSC is due by differentiation of the cancer stem cells into 
non-CSC rather then selectively inducing apoptosis in the cancer stem cells. 
The effect of MDM2/p53 binding inhibition by MI-773 on HMC cell number 
To determine any the presence of off target effects of MI-773 in targeting the 
MDM2/p53 interaction, we used shRNA vectors to silence p53 expression in UM-HMC-
3A cells. shp53 #1 and shp53 #2 vectors showed reduction in p53 expression while 
shp53 #2 showed little decrease in p53 expression compared to the shControl vector 
(Figure IV.4B). Interestingly, we also saw a significant reduction in MDM2 and p21 
(Figure IV.4B). Using these cells, we performed a WST-1 analysis treating the p53 
silenced and control cells with varying concentration of MI-773. The shControl cells 
showed an IC50 value of 4.6uM while shp53 #1, shp53 #2, and shp53 #3 cells showed 
IC50 values of 67.9uM, 18.4uM, and 59.7uM respectively (Figure IV.4A). These results 
demonstrate that silencing of p53 confers resistance of UM-HMC-3A cells to MI-773 
treatment and suggests that the therapeutic effect of MI-773 is primarily through p53 
activation.  
 To determine the overall effect of MI-773 on HMC cell number and expression of 
proteins downstream of p53, we performed WST-1 and western blot analysis on UM-
HMC-1, UM-HMC-3A, and UM-HMC-3B unsorted cells. When UM-HMC-1 cells were 
subjected to varying concentrations of MI-773 for 24, 48, and 72 hours, we saw a 
significant decrease in the total cell number. While 24-hour treatment had little effect on 
the number of cells, the IC50 at 48 and 72 hours was 37.9uM and 0.9uM respectively  
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Figure IV.4. The effect of MDM2/p53 binding inhibition by MI-773 on HMC cell number. A, 
WST-1 analysis of UM-HMC-3A shcontrol and shp53 cells. p53 was knocked down using three 
different lentiviral shp53 vectors. Transfected cells were plated at 500 cells per well and 
exposed to varying concentrations of MI-773 for 72 hours. After 4 hours of incubation with WST-
1, the plates were analyzed and normalized to a DMSO control. B, Western blot analysis of 
lysates created from shp53 knockdown cells. C, WST-1 analysis of UM-HMC-1 cells treated 
with varying concentrations of MI-773 for 24, 28, and 72 hours. UM-HMC-1 cells were seated at 
500 cells per well. After each time point, 10uL of WST-1 reagent was added to the cells for 4 
hours and then analyzed. All cells were normalized to a DMSO control. D, Western blot analysis 
of UM-HMC-1 cells treated with 0.1, 1, 10, or 20 uM MI-773 for 24 hours. E, WST-1 analysis of 
UM-HMC-3A cells treated with varying concentrations of MI-773 for 24, 28, and 72 hours. UM-
HMC-3A cells were seated at 500 cells per well. After each time point, 10uL of WST-1 reagent 
was added to the cells for 4 hours and then analyzed. All cells were normalized to a DMSO 
control. F, Western blot analysis of UM-HMC-3A cells treated with 0.1, 1, 10, or 20 uM MI-773 
for 24 hours. G, WST-1 analysis of UM-HMC-3B cells treated with varying concentrations of MI-
773 for 24, 28, and 72 hours. UM-HMC-3B cells were seated at 500 cells per well. After each 
time point, 10uL of WST-1 reagent was added to the cells for 4 hours and then analyzed. All 
cells were normalized to a DMSO control. H, Western blot analysis of UM-HMC-3B cells treated 
with 0.1, 1, 10, or 20 uM MI-773 for 24 hours. 
 
(Figure IV.4C). We next treated UM-HMC-1 cells with 0uM, 0.1uM, 1uM, 10uM, and 
20uM MI-773 and made lysates for western blot analysis. With increasing 
concentrations of MI-773, we saw a robust accumulation of p53 and and increase in 
MDM2 and p21 expression suggesting that p53 is indeed activated (Figure IV.4D). 
Interestingly, we also saw a dramatic reduction of self-renewal marker, Bmi-1, 
suggesting that we are indeed reducing the cancer stem cell population upon treatment 
with MI-773 (Figure IV.4C). We next performed WST-1 analysis using UM-HMC-3A 
cells and again saw a significant reduction in the number of cells, particularly after 48 
and 72 hours of treatment, with IC50 values measured at 9.93uM and 5.94uM 
respectively (Figure IV.4E). Once again, we saw a dramatic increase in expression of 
MDM2, p53, and p21 and a reduction in Bmi-1 expression again suggesting that p53 is 
indeed activated upon treatment with MI-773 and that the MI-773 reduces the CSC 
population (Figure IV.4F). Finally, we performed WST-1 and western blot analysis on 
treated UM-HMC-3B cells a found a drastically different trend. Upon treatment with MI-
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773, UM-HMC-3B cells showed significantly higher IC50 values when compared to UM-
HMC-1 and UM-HMC-3A at 24, 48, and 72 hours treatments (IC50 values were 
100.1uM, 97.0uM, and 64.8uM respectively) (Figure IV.4G). When western blot analysis 
was performed, we saw little to no increase in MDM2, p53, or p21 expression (Figure 
IV.4H). Interestingly, we again observe a reduction in Bmi-1 expression, suggesting that 
while the overall cell number is not affected by MI-773, the CSC population is still 
susceptible to MI-773 treatment.  
 Overall, our data suggests that MI-773 is able to effectively reduce cell number in 
UM-HMC-1 and UM-HMC-3A cells. While the proliferative activity of UM-HMC-3B cells 
showed little sensitivity to MI-773, we conclude that the agent is capable of reducing the 
number of  cancer stem-like cells in all cell lines. 
Induction of cell cycle arrest and apoptosis in HMC cells by MI-773 
To investigate the mechanism by which MI-773 is able to reduce HMC cell 
populations, we treated HMC cells with 1uM MI-773 and stained with propidium iodide 
to assess cell cycle status. We treated the UM-HMC-3A cells with 1uM MI-773 to 
determine the cell cycle profile of the treated versus untreated cells. After both 24 and 
48 hours, we observed and increase of cells in G1 and a decrease in cells in both S and 
G2, suggesting that MI-773 induces G1 cell cycle arrest in UM-HMC-3A cells (Figure 
IV.5A). We next treated our UM-HMC-3A cells with 5uM, 10uM, and 15uM MI-773 for 24 
hours to see if MI-773 treatment induced apoptosis. After treatment, the cells were 
stained with both 7AAD and Annexin-V. We observed an increase of cells positive for 
Annexin-V alone (early apoptosis) as well as cells positive for both Annexin-V and 
7AAD (late apoptosis) (Figure IV.5B). 
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Figure IV.5. Induction of cell cycle arrest and apoptosis in HMC cells by MI-773. A, Cell 
cycle analysis of UM-HMC-3A cells treated with 1uM MI-773 for 24 and 48 hours. Cells were 
plated at 500,000 cells per flask. Control cells were treated with DMSO. B, Annexin V and 7AAD 
FACS analysis following treatment of UM-HMC-3A cells with 5, 10, or 15 uM MI-773 for 24 
hours. Control cells were treated with DMSO. C, Cell cycle analysis of UM-HMC-3B cells treated 
with 1uM MI-773 for 24 and 48 hours. Cells were plated at 500,000 cells per flask. Control cells 
were treated with DMSO. D, Annexin V and 7AAD FACS analysis following treatment of UM-
HMC-3B cells with 5, 10, or 15 uM MI-773 for 24 hours. Control cells were treated with DMSO. 
E, Apoptosis Antibody Array (R&D) analysis in UM-HMC-3A cells treated with 5uM MI-773 for 
24 hours. F, Blot from Apoptosis Array was quantitated using ImageJ software. Blot quantitation 
for MI-773 treated lysates were normalized to the values of the DMSO treated blots. 
 
Since UM-HMC-3B cells are uniquely resistant to MI-773 treatment, we sought to 
verify that MI-773 is incapable of inducing cell cycle arrest in this population. Upon 
treatment with 1uM of MI-773 for 24 or 48 hours, we observed no difference in the cell 
cycle profile in treated cells versus control cells consistent with our previous results 
(Figure IV.5C). To determine whether MI-773 was able to induce apoptosis in UM-HMC-
3B cells, we treated the cells with 5uM, 10uM, and 15uM MI-773 for 24 hours. Following 
treatment we stained the cells for both Annexin-V and 7AAD and saw no difference in 
percentage of 7AAD positive cells or Annexin-V and 7AAD positive cells in the control 
treated versus the MI-773 treated (Figure IV.5D). Again, these results further confirm 
that UM-HMC-3B cells are resistant to MI-773 induced cell cycle arrest and apoptosis.  
To identify the apoptotic pathways upregulated upon treatment with MI-773, we 
treated UM-HMC-3A cells with 5uM MI-773 for 24 hours and ran the Apoptosis Antibody 
Array (R&D). We observed a significant up regulation of pro-apoptotic proteins such as 
Bcl-x, cleaved caspase-3, cytochrome c, p21, p27, and phosphorylated p53 (Figure 
IV.5E and 5F). Together these results suggest that treatment with MI-773 is capable of 
inducing p53 induced G1 cells cycle arrest and apoptosis in UM-HMC-3A. In contrast, 
MI-773 was unable to induce cell cycle arrest or apoptosis in UM-HMC-3B cells.  
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Figure IV.6. Effect of MDM2/p53 binding inhibition by MI-773 on cancer stem cells in UM-
HMC-3A cells in-vivo. A, Graph depicting the tumor volume during 6 days of 50mg/kg 
treatment with MI-773. 600,000 UM-HMC-3A cells were co-implanted with 400,000 human 
endothelial cells (HDMEC) on biodegradable scaffolds in the subcutaneous space of SCID 
mice. Once tumor reached an average volume of 500mm3, the mice were treated by daily oral 
gavage with 50mg/kg MI-773 or a vehicle control. B, Graph depicting the average mouse weight 
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during the 6-day treatment sequence. C, Graph depicting the percentage of ALDHhighCD44high 
cells in MI-773 treated tumors. After 6 days of treatment, the tumors were resected and digested 
into a single cells suspension. The cells were then stained and FACS analyzed. D, Graph 
depicting the pixel density per field of sections stained for TUNEL in MI-773 or vehicle treated 
tumors. Seven fields at 200X were taken per tumor section and quantified using the ImageJ 
software. Error bars indicated the standard error of the mean. E, Immunohistochemistry and 
immunofluorescence analysis of MI-773 or vehicle treated tumors. Immunohistochemistry 
images were taken at 100x and the immunofluorescence images were taken at 200X.  
 
Consistent with our previous results, UM-HMC-3B cells are resistant to MI-773 
treatment. 
Effect of MDM2/p53 binding inhibition by MI-773 on cancer stem cells in UM-HMC-
3A cells in-vivo 
To determine the therapeutic efficacy of MI-773 in reducing tumor volume and 
ablating cancer stem cells in-vivo, we co-implanted UM-HMC-3A cells with human 
endothelial cells (HDMEC) on a biodegradable scaffold in mice as previously described 
(30). Once the tumors reached an average volume of 500mm3, the mice were treated 
daily for six days with 50mg/kg MI-773 by oral gavage. After the six-day treatment cycle, 
we began to see a regression in tumor volume compared to the vehicle treated tumors 
(Figure IV.6A).To measure the presence of any toxic effects in the mice, we monitored 
the weight of the mouse with each treatment (Figure IV.6B). While the mouse weight in 
the treated group was slightly reduced during treatment, much of the weight loss was 
recovered by the end of treatment.  
At day seven, the tumors were removed and digested into single cells 
suspensions for FACS analysis. After staining the cells for ALDH/CD44, we observed a 
reduction in the ALDHhighCD44high cancer stem cells population, consistent with our 
previous observation in-vitro (Figure IV.6C). To further validate this finding, tumor tissue 
sections were stained for ALDH/CD44. We also observed a reduction in the presence of 
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ALDH/CD44 positive cells (Figure IV.6E). Tissue sections were also stained for TUNEL 
to determine the number of cells undergoing apoptosis (Figure IV.6D and  6E). The 
pixel density of the images was quantitated using ImageJ and we observed a significant 
increase in the pixel density of the images in the MI-773 treated tumors when compared 
to the vehicle treated tumors (Figure IV.6D).  Tumor tissue sections were also stained 
with p53 and MDM2 to determine if both proteins were upregulated upon activation of 
p53. In the MI-773 treated tumors compared to the vehicle treated tumors, we saw an 
increase in both p53 and MDM2 expression (Figure IV.6E).  
To test whether a higher treatment dose of MI-773 would be more effective in 
reducing tumor volume and ablating cancer stem cells, we performed a second six-day 
in-vivo study administering 100mg/kg MI-773. Once again, 600,000 UM-HMC-3A cells 
were co-implanted with 400,000 HDMEC cells on biodegradable scaffolds and 
implanted subcutaneously in SCID mice. When the tumors reached an average volume 
of 500mm3, the mice were treated with 100mg/kg MI-773 by daily oral gavage for six 
days and tumor volume measurements were taken daily. Overall we observed a 
decrease in tumor volume in mice treated with MI-773 compared to vehicle treated 
tumors (Figure IV.7A). To assess any toxic effects, we measured the mouse weight 
daily and observed a slight decrease in MI-773 treated mouse weight (Figure IV.7B). 
After six days of treatment, the tumors were resected and tissue sections were stained 
for MDM2 and p53 to ensure that p53 was indeed activated upon treatment with MI-773.  
Immunohistochemistry staining revealed an increase in expression of both 





Figure IV.7. Effect of 100mg/kg treatment of MI-773 on UM-HMC-3A cells. A, Graph 
depicting the tumor volume during 6 days of 100mg/kg treatment with MI-773. 600,000 UM-
HMC-3A cells were co-implanted with 400,000 human endothelial cells (HDMEC) on 
biodegradable scaffolds in the subcutaneous space of SCID mice. Once tumor reached an 
average volume of 500mm3, the mice were treated by daily oral gavage with 100mg/kg MI-773 
or a vehicle control. B, Graph depicting the average mouse weight during the 6-day treatment 
sequence. C, Immunohistochemistry and immunofluorescence analysis of MI-773 or vehicle 
treated tumors. Immunohistochemistry  and immunofluorescence images were taken at 200x. D, 
Graph depicting the pixel density per field of sections stained for TUNEL in MI-773 or vehicle 
treated tumors. Seven fields at 200X were taken per tumor section and quantified using the 
ImageJ software. Error bars indicated the standard error of the mean. E, Western blot analysis 
of MI-773 and vehicle treated tumors. 
 
suggesting that p53 signaling was indeed activated (Figure IV.7C and 7E). We also 
observed an increased expression of p21 further confirming that p53 signaling pathways 
were indeed activated (Figure IV.7E). In addition to immunohistochemistry staining, we 
performed TUNEL staining to determine if 100mg/kg MI-773 was able to induce 
apoptosis in UM-HMC-3A tumors. Images of TUNEL staining showed an increased in 
the number of TUNEL positive cells in MI-773 treated tumors compared to vehicle 
treated tumors (Figure IV.7C). The pixel density of the images was quantitated and also 
showed an increase in the average pixel density per field in the treated versus control 
tumors (Figure IV.7D). Remaining tumor tissue was digested into a single cell 
suspension and stained for ALDH/CD44 to determine the percentage of cancer stem 
cells, however, no reduction was observed suggesting that this may be a dose 
dependent effect (data not shown). Immunofluorescence staining of ALDH/CD44 also 
revealed similar expression of both ALDH and CD44, however, western blot analysis 
does show a decreased expression of Bmi-1 suggesting some loss of stem cell 
associated functions (Figure IV.7C and 7E).  
Overall our results confirm our findings in-vivo for UM-HMC-3A. We conclude 
that MI-773 is effective in reducing tumor volume and inducing p53 signaling thereby 
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initiating apoptosis in the UM-HMC-3A cells. We also conclude that MI-773 is an 
effective agent in reducing the cancer stem cell population in UM-HMC-3A cells when 
treated with low doses of the drug. 
Effect of MDM2/p53 binding inhibition by MI-773 on cancer stem cells in UM-HMC-
3B cells in-vivo 
As the UM-HMC-3B cell line responded differently than the UM-HMC-3A cells in-
vitro when treated with MI-773, we next sought to see if these results were consistent 
in-vivo. As UM-HMC-3B cells were so resistant to MI-773 in-vitro, we treated our in-vivo 
model with a higher treatment dose. Once again, we implanted 600,000 UM-HMC-3B 
cells with 400,000 HDMEC cells on biodegradable scaffolds and implanted them 
subcutaneously in SCID mice. We administered 100mg/kg MI-773 for six days by oral 
gavage. On the seventh day, the tumors were resected and analyzed. Overall, we saw 
little difference in tumor volume, again suggesting that these tumors are resistant to MI-
773 treatments (Figure IV.8A). We monitored the mouse weight daily to identify any 
toxic effects but no decrease in mouse weight indicating that the mice tolerated the 
treatment (Figure IV.8B).  
While there was little effect on overall tumor volume, we next were interested if 
the cancer stem cell population was affected despite the lack of tumor shrinkage. After 
the tumors were resected, we digested the tissue into a single cell suspension and 
stained for FACS analysis. Upon staining for ALDH activity and CD44 expression, we 
observed a drastic decrease in the ALDHhighCD44high cancer stem cell population in the 
MI-773 treated versus the vehicle treated (Figure IV.8C). We confirmed these results by 
ALDH/CD44 immunofluorescence staining in MI-773 treated tumors versus vehicle 
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treated tumors (Figure IV.8E). To determine if p53 was activated upon MI-773 
treatment, we performed immunohistochemistry staining on drug treated and vehicle- 
 
Figure IV.8. Effect of MDM2/p53 binding inhibition by MI-773 on cancer stem cells in UM-
HMC-3B cells in-vivo. A, Graph depicting the tumor volume during 6 days of 100mg/kg 
treatment with MI-773. 600,000 UM-HMC-3B cells were co-implanted with 400,000 human 
endothelial cells (HDMEC) on biodegradable scaffolds in the subcutaneous space of SCID 
mice. Once tumor reached an average volume of 500mm3, the mice were treated by daily oral 
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gavage with 100mg/kg MI-773 or a vehicle control. B, Graph depicting the average mouse 
weight during the 6-day treatment sequence. C, Graph depicting the percentage of 
ALDHhighCD44high cells in MI-773 treated tumors. After 6 days of treatment, the tumors were 
resected and digested into a single cells suspension. The cells were then stained and FACS 
analyzed. A t-test was used to test for significance. D, Graph depicting the pixel density per field 
of sections stained for TUNEL in MI-773 or vehicle treated tumors. Seven fields at 200X were 
taken per tumor section and quantified using the ImageJ software. Error bars indicated the 
standard error of the mean. E, Immunohistochemistry and immunofluorescence analysis of MI-
773 or vehicle treated tumors. Immunohistochemistry images were taken at 100x and the 
immunofluorescence images were taken at 200X. 
 
treated tumor sections and saw a slight increase in expression of both p53 and MDM2 
(Figure IV.8E). To determine whether or not there was any induction of apoptosis in the 
tumors, we performed TUNEL staining and quantitated the images using ImageJ 
software. In the images, we observed an increased number of cells that were TUNEL-
positive suggesting that MI-773 treatment induced apoptosis in UM-HMC-3B cells in-
vivo (Figure IV.8D and 8E).Together these results suggest that MI-773 is a potent agent 
in reducing the cancer stem cells in UM-HMC-3B generated tumors. We also conclude 
that MI-773 is capable of inducing apoptosis of UM-HMC-3B. 
To determine whether or not a higher dose of MI-773 would be more effective in 
reducing tumor volume, we implanted UM-HMC-3B cells as described above and 
treated the mice for 5 days with 200mg/kg MI-773 by daily oral gavage. After five days 
of treatment, the tumors were resected and analyzed. Over the five-day treatment cycle, 
we saw little reduction in overall tumor volume and saw a decrease in the MI-773-
treated mouse weight suggesting the presence of toxic effects (Figure IV.9A and 9B). 
Interestingly we did see a greater accumulation of p53 and a decreased expression of 
G1 cell cycle associated proteins Cyclin A, Cyclin D1, Cyclin E, CDK2, CDK4, and 




Figure IV.9. Effect of 200mg/kg treatment on UM-HMC-3B cells in-vivo. A, Graph depicting 
the tumor volume during 6 days of 100mg/kg treatment with MI-773. 600,000 UM-HMC-3A cells 
were co-implanted with 400,000 human endothelial cells (HDMEC) on biodegradable scaffolds 
in the subcutaneous space of SCID mice. Once tumor reached an average volume of 500mm3, 
the mice were treated by daily oral gavage with 100mg/kg MI-773 or a vehicle control. B, Graph 
depicting the average mouse weight during the 6-day treatment sequence. C, 
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Immunohistochemistry staining for p53 in sections from the vehicle and MI-773 treated tumors. 
D, Western blot analysis of vehicle and MI-773 treated tumor tissues for G1 cells cycle-
associated proteins. E, Immunofluorescence staining for ALDH/CD44 and TUNEL in vehicle and 
MI-773 treated tumors. F, Graph depicting the pixel density per field of sections stained for 
TUNEL in MI-773 or vehicle treated tumors. Seven fields at 200X were taken per tumor section 
and quantified using the ImageJ software. Error bars indicated the standard error of the mean. 
 
 
(Figure IV.9C and 9D). These results suggest that we were able to activate p53 
signaling and induce G1 cell cycle arrest in the tumors.  
Once the tumor tissue were dissociated, we stained for ALDH activity and CD44 
expression and saw a slight decrease in the ALDHhighCD44high population though the 
difference was not significant again suggesting that the effect on the cancer stem cell 
population is dose dependent (data not shown). We also performed 
immunofluorescence staining for ALDH/CD44 expression and once again observed a  
decrease in the number of ALDHhighCD44high cells (Figure IV.9E). To determine whether 
or not MI-773 treatment induced apoptosis, we performed TUNEL staining and 
quantitated the pixel density of the images. We did observe an increase in the number 
of TUNEL positive cells in the MI-773 treated tumors compared to the vehicle treated 
tumors (Figure IV.9E and 9F).  
Together these results confirm our in-vitro findings that while UM-HMC-3B cells 
are more resistant to MI-773 treatment, this drug serves as an effective agent in 
reducing the cancer stem cells population. However, this effect appears to be more 
robust when mice are treated with lower doses of the drug. Interestingly, with 100mg/kg 
and 200mg/kg doses of MI-773 we did observe an induction of apoptosis suggesting the 





Resistance to chemotherapy and radiation treatments poses a clinical barrier to 
effectively treating patients with advanced stage mucoepidermoid carcinomas. Previous 
research indicates that cancer stem cells play a critical role in resistance to therapy and 
disease recurrence (12, 31-32). Studies from our laboratory identified cancer stem cells 
in salivary gland mucoepidermoid carcinoma (16). This aggressive subpopulation can 
be isolated using an ALDHhighCD44high marker combination. Importantly, we found that 
ALDHhighCD44high cells are uniquely tumorigenic compared to ALDHlowCD44low cells and 
are able to self renew and differentiate into non-cancer stem cells. Because of CSC 
resistance to treatment, novel therapies are needed to ablate this uniquely tumorigenic 
population of cancer stem cells. Already a great deal of research has been done in an 
effort to target stem cell associated pathways aiming to selectively eliminate the cancer 
stem cell population in other cancer types. Such pathways include Notch, Wnt, 
Hedgehog, IL-6, Her-2, and PI3K/AKT (33-36). For many of these pathways, lack of 
specific targeted agents poses a barrier to effective elimination of the cancer stem cell 
population.  
Tumor-suppressor protein p53 plays a critical role in regulating the cell cycle and 
senescence as well as inducing apoptosis upon oncogenic stress. Importantly, research 
also suggests that p53 plays an important role in normal stem cell function by actively 
initiating or repressing several stem cell-associated proteins such as Nanog and Oct-4, 
making it an intriguing pathway to study in the context of cancer stem cells (37). Studies 
suggest that in the absence of p53, both normal and tumor cells acquire dedifferentiated 
phenotypes (20-25). MDM2, the main regulator of p53, functions as a E3 ubiquitin ligase 
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signaling p53 for degradation and can also bind p53 to block the transactivation domain 
of the protein. Inhibition of MDM2 binding to p53 prevents p53 degradation causing an 
accumulation of p53 in the cell. Many groups have sought to develop small molecule 
inhibitors to block MDM2/p53 binding interactions, however, most lack specificity to be 
effective therapeutically (38-42).  
 One promising molecule, MI-773, is significantly more specific and shows 
improved anti-tumor efficacy when compared to other MDM2 inhibitors (27). Upon 
treatment with MI-773 either in-vitro or in-vivo, Wang et al observed a significant 
induction of p53 signaling in a variety of different cancer types (27). Activation of p53 
within these cells induced apoptosis, which in turn caused significant tumor shrinkage in 
in-vivo models (27). Importantly, in our studies, MI-773 showed significant therapeutic 
efficacy against both cancer stem cells and differentiated mucoepidermoid carcinoma 
cells. Upon treatment with low-dose MI-773, we observed a significant reduction of 
ALDHhighCD44high cancer stem cells in our HMC cells lines both in-vitro and in-vivo. 
Interesting, when we treated both ALDHhighCD44high and non-CSC cells with varying 
concentrations of MI-773, we saw no difference in the total cell density suggesting that 
the reduction in ALDHhighCD44high cells is due to differentiation rather then apoptosis or 
senescence. To further support this conclusion, we observed a drastic reduction in the 
self-renewal associated protein, Bmi-1, and a significant increase in differentiation-
associated protein, p21.  
In addition to inducing differentiation of cancer stem cells, our results show that 
MI-773 is able to induce both cell cycle arrest and apoptosis in the UM-HMC-1 and UM-
HMC-3A cells in-vivo and in-vitro suggesting that this drug may be an efficacious 
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treatment for MEC patients. Interestingly, UM-HMC-3B cells were highly resistant to MI-
773 induced apoptosis and cell cycle arrest but very susceptible to MI-773 ablation of 
the cancer stem cell population. A possible explanation is because MDM2 expression 
was higher in ALDHhighCD44high cells compared to non-CSC suggesting that the cancer 
stem cells may be more susceptible to MDM2 inhibition. Importantly, we also observed 
an increase in TUNEL-positive cells and a decrease in the expression of G1 cell cycle-
associated proteins in our UM-HMC-3B in-vivo studies, suggesting that treatment with 
MI-773 could be more efficacious over longer time periods. In our mouse models, we 
co-implant the HMC cells with human endothelial cells to generate a supportive 
microenvironment. While outside the scope of this study, we hypothesize that some of 
the therapeutic effect in UM-HMC-3B cells upon treatment with MI-773 could also be 
due to the disruption of the vasculature within the tumors. 
While little is known about the role of p53 and MDM2 in salivary gland 
mucoepidermoid carcinomas, several sequencing and immunohistochemistry studies 
suggest that p53 mutations and loss of heterozygosity are rare events (43-47). 
Interestingly, after performing PCR amplification and Sanger sequencing, we observed 
p53 mutations in our UM-HMC-1, UM-HMC-3A, and UM-HMC-3B cell lines.  All three 
cell lines showed an A278P mutation which has also been seen in other cancer types. 
No studies have identified any functional deficiencies in p53 in cancer cells that have 
this mutation (48-49). UM-HMC-3A and UM-HMC-3B also showed a mutation at V157F, 
which studies suggest does structurally alter p53 (50). Interestingly, neither mutation 
occurs within the MDM2 binding region of p53. While MDM2 inhibitors were previously 
thought to be dependent on the presence of wild-type p53, studies suggest that MI-773 
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functions in cells containing mutant p53, depending on the mutation (28). In our 
experiments, UM-HMC-1 and UM-HMC-3A cells were susceptible to MI-773 treatment 
despite the presence of p53 mutations suggesting that the mutations are either non-
interfering or that the mutations are heterozygous. Interestingly, while UM-HMC-3A and 
UM-HMC-3B cells have the same acquired mutations, only UM-HMC-3B cells were 
resistant, suggesting that UM-HMC-3B cells may have a homozygous mutation. 
Collectively, this work demonstrates that inhibition of p53 and MDM2 binding 
effectively targets ALDHhighCD44high cancer stem cells in salivary gland mucoepidermoid 
carcinoma through activation of p53 and differentiation of the cells into non-cancer stem 
cells both in-vitro and in-vivo. Activation of p53 by inhibition of MDM2 binding also 
induces cells cycle arrest and apoptosis in mucoepidermoid carcinoma cells in-vitro and 
in-vivo leading to cell death and tumor shrinkage. These results suggests that patients 
with mucoepidermoid carcinomas may benefit from MDM2 inhibition therapies that 
target both the cancer stem cells and bulk cell populations.  
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Summary and Discussion 
Introduction 
 Significant advancements have been made in the diagnosis and treatment of 
many types of cancer. While cancer still remains a significant clinical challenge 
worldwide, better therapies and diagnostic tools have helped reduce the impact of this 
disease. Sadly, little to no progress has been made in improving patient outcome of 
those diagnosed with salivary gland cancer. Importantly, salivary gland cancers are 
extremely heterogeneous and composed of many different subtypes making correct 
diagnosis of the tumor difficult. Due to the infrequency of salivary gland cancers and the 
difficulty in obtaining adequate research models, we have a poor understanding of the 
underlying biology that drives the persistent and relentless growth of these tumors.  
 Due to the generous donations of patients diagnosed with the most common 
from of salivary gland cancer, mucoepidermoid carcinoma, our laboratory has 
generated some of the first tumorigenic cell lines from tumor tissues resected from 
these patients (1). Using the cell lines, we have generated mouse xenograft models to 
better understand the biology of these tumors in an in-vivo model. Using these tools, we 
sought to better understand the biology driving the growth of aggressive and recurrent 
mucoepidermoid carcinomas. Below is summarized the chapters of this thesis detailing 
the observations and conclusions of our first projects studying mucoepidermoid
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carcinoma. Chapter II consists of a review of the literature to give background for our 
overall hypothesis and specific aims found in chapters III and IV. 
Summary of Chapters 
CHAPTER II: The salivary glands play a critical role in the maintenance and function of 
the oral cavity. Both the major salivary and the minor salivary glands are essential for 
the lubrication and taste of food as well as proper speech. While rare, salivary gland 
tissue is susceptible to malignant cancerous growth. The most common form of salivary 
gland cancer, mucoepidermoid carcinoma, remains a significant threat to those who 
have been diagnosed (2). Of primary interest is the high level of recurrence seen within 
the patients and chemotherapy resistance of these tumors. Surgical resection and 
irradiation of less aggressive, low to intermediate-grade tumors is often successful. 
However, patients with aggressive high-grade tumors or patients with recurrent disease 
have few treatment options.  
 One hypothesis, the cancer stem cell hypothesis, has been used to explain the 
high rate of recurrence following chemotherapy and radiation treatments. Researchers 
have found a specific subpopulation of highly tumorigenic, stem-like cells that are not 
only capable of forming tumors using a low number of cells but also have the ability to 
differentiate and self-renew. These cancer stem cells are highly resistant to 
chemotherapy and radiation treatments.  
 Researchers identified cancer stem cell markers in head and neck squamous cell 
carcinoma using the ALDH/CD44 marker combination. Early studies identified both 
ALDH and CD44 individually as possible markers for cancer stem cells, however, 
combined sorting of ALDHhighCD44high staining cells isolated cells capable of forming 
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tumors in mice with as few as 1,000 cells whereas 10,000 ALDHlowCD44low cells were 
needed to form tumors (3). Importantly, studies have shown that ALDHhighCD44high 
cancer stem cells resided in perivascular niches rich in blood vessels and were 
supported by the surrounding endothelial cells. 
 Little research has been done to identify and isolate cancer stem cells in salivary 
gland mucoepidermoid carcinoma. However, researchers were able to isolate cancer 
stem cells in adenoid cystic carcinoma using high ALDH activity (4). ALDHhigh cells 
showed an increased ability to form spheres under low-attachment, serum-free 
conditions. As few as 100 ALDHhigh cells were capable of forming tumors in-vivo 
suggesting that this is indeed a population of cancer stem cells. Research is still needed 
to identify this population of cells in mucoepidermoid carcinoma.  
Chapter III: To determine whether or not cancer stem cells exist within mucoepidermoid 
carcinoma, we first sought to determine the expression patterns of commonly used 
cancer stem cell markers (ALDH, CD10, CD24, CD44) in mucoepidermoid carcinoma 
patient samples using immunofluorescence imaging. We observed that ALDH and 
CD44 showed positive staining in almost all samples while CD10 and CD24 staining 
was variable. When normal salivary gland tissue was compared to less aggressive 
cystic and more aggressive solid tumor, we observed an increase in expression of all 
four markers suggesting that these proteins are associated with more aggressive 
disease. 
 To begin to functionally analyze these markers as stem cell markers, sorted UM-
HMC-3A and UM-HMC-3B cells into ALDH/CD44, CD10/CD24, CD44/CD24, and 
CD10/CD24 and plated the different subpopulations in low-attachment, serum-free 
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conditions. We observed robust sphere formation in the ALDHhighCD44high cell 
population compared to the ALDHlowCD44low cells in both cell lines. Specific 
subpopulations of CD10/CD24, CD44/CD24, and CD10/CD24 sorted cells formed more 
salispheres, however, the outgrowing population was not the same between the two cell 
lines tested. 
 To determine the tumorigenic potential of the different subpopulations in the four 
marker combinations, we sorted UM-HMC-3A and UM-HMC-3B cells for 
ALDHhighCD44high and ALDHlowCD44low and implanted them in-vivo. Overall, we were 
able to generate tumors in 18 of the 36 scaffold implanted with 400 ALDHhighCD44high 
cells and only 1 of the 36 scaffolds implanted with 4,000 ALDHlowCD44low cells. 
Importantly, mice implanted with 5,000 ALDHhighCD44high cells reached palpability more 
quickly and grew tumors significantly faster then mice implanted with ALDHlowCD44low 
cells. 
 While cells sorted for CD10/CD24 and CD10/CD44 showed little tumorigenic 
potential in our mouse models, cells sorted for the four different CD44/CD24 
subpopulations did show significant differences in tumorigenicity in-vivo. However, the 
differences observed were not repeatable in low-passage versus high-passage 
xenograft models suggesting that this marker combination does not identify and isolate 
a cancer stem cell population.  
 Together we conclude that ALDHhighCD44high marker combination identifies a 
population of cancer stem cells capable of self-renewal and differentiation as well as 
high tumorigenic potential.   
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CHAPTER IV: To determine if p53 plays a role in cancer stem cell biology and to 
determine if MDM2 inhibition is effective in therapeutically ablating the aggressive 
ALDHhighCD44high cancer stem cells, we treated UM-HMC-1, UM-HMC-3A, and UM-
HMC-3B cells with 1uM MI-773 to bind MDM2 and prevent inhibition of p53 functioning 
in the cell. Upon 48, 72, and 96-hour treatments with MI-773, we observed a drastic 
reduction of ALDHhighCD44high cancer stem cells upon FACS analysis. Interestingly, 
when HMC cells were sorted for CSC and non-CSC then treated with MI-773, we 
observed no difference in the total number of CSC and non-CSC treated cells. This 
suggests that MI-773 primarily acts by causing differentiation of the ALDHhighCD44high 
cells rather than preferentially inducing apoptosis in the CSC versus non-CSC. 
Importantly, treatment of HMC cells with MI-773 increased expression of p53, 
MDM2, and p21 indicating that p53 signaling is indeed activated. We also observed a 
dramatic decrease in Bmi-1 expression again indicating that activation the p53 reduces 
the stemness of the treated cells. In addition to activating p53 signaling and reducing 
the cancer stem cell population, we also observed an induction of cell cycle arrest and 
apoptosis in HMC cells in-vitro when treated with varying concentrations of MI-773. 
 To determine whether MI-773 treatment is effective in ablating cancer stem cells 
in-vivo we implanted UM-HMC-3A and UM-HMC-3B cells and treated the tumors with 
50mg/kg or 100mg/kg respectively. Following six days of treatment, the tumors were 
excised and digested for FACS analysis. When compared to vehicle treated tumors, MI-
773 treated tumors showed a dramatic reduction in the percentage of ALDHhighCD44high 
cancer stem cells, similar to the results we observed in-vitro. We also observed an 
increase in the number of TUNEL positive cells suggesting that MI-773 is also capable 
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of inducing apoptosis of HMC cells in-vivo through an activation of p53 signaling by the 
increase in expression of both MDM2 and p53.   
 Together, we conclude that MDM2 and p53 play a critical role in cancer stem cell 
biology. We also conclude that therapeutic inhibition of MDM2 binding to p53 is not only 
effective in inducing apoptosis and cell cycle arrest, but also in ablating cancer stem 
cells from the tumor both in-vitro and in-vivo.  
Future Directions 
 While the research presented here elucidates some of the biology important to 
the growth of salivary gland mucoepidermoid carcinomas, many questions concerning 
pathobiology of this cancer type remain. Further research will be critical to bettering the 
outcome of patients diagnosed with this cancer, of particular interest is better 
understanding of ALDHhighCD44high cancer stem-like cells. While p53 appears to play an 
important role in inducing differentiation, other stem cell pathways such as PI3K/AKT 
also play an important role in mucoepidermoid carcinoma (5). Interestingly, we found 
this pathway to be activated in HMC cancer stem cells. Therapeutic targeting of these 
pathways could also be potentially effective in reducing cancer stem cells.  
 In our studies presented here, we identified p53 as an important protein in 
decreasing the ALDHhighCD44high cancer stem cells. While preliminary studies lead us to 
believe that this effect is due to p53 induced differentiation, further mechanistic 
investigation of p53 in MEC cancer stem cells is needed in order to more fully 
understand the role of p53 in cancer stem cell biology. 
The primary purpose of studying the drug MI-773 was to observe the effect of 
MDM2 inhibition directly on the mucoepidermoid carcinoma cells. However, MDM2 
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inhibition could also have a drastic effect on the cells surrounding and supporting the 
cancer cells within the tumor. Tumors contain a heterogeneous population of cells that 
create a supportive microenvironment for the cancer cells to grow in. In our mouse 
models, we co-implanted HMC cancer cells with human endothelial cells to replicate the 
perivascular niche within tumors. As endothelial cells express wild-type p53 and MDM2, 
MI-773 could also be inducing apoptosis in these human and mouse endothelial cells 
thereby destroying the blood supply to the tumor environment.  
Final Remarks 
The cancer stem cell hypothesis was proposed many years ago, however, only 
within the last 15 years have we begun to identify and functionally characterize these 
cells (6-7). While most accept the concept of tumor heterogeneity, many do not believe 
stem cells to be the origin of cancer growth or that tumors grow in a hierarchical 
manner. Small populations of cancer stem cells have been identified in many solid 
malignancies, however, several have suggested that the use of immunodeficient mice 
and consequent lack of a human microenvironment is responsible for the difference in 
growth and tumor initiation (8-10).  A previous study compared the growth of melanoma 
cells in NOD/SCID mice versus NOG mice and found that while only one in 100,000 
cells were able to generate a tumor in the NOD/SCID mice while one in four cells was 
able to generate a tumor in the NOG mice suggesting that differences in surrounding 
microenvironment have a profound impact on the growth of the human cells (10). 
Unfortunately, full replication of the human microenviroment within a mouse model is 
complex. In our studies here, we co-implanted HMC cells with human endothelial cells 
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to create a more human derived microenvironment, however, we acknowledge that this 
is also a limitation of our study.  
Another point of controversy within the cancer stem cell hypothesis is whether 
the cancer stem cells arise from actual tissue specific stem cells (11). The slow rate of 
division and longevity of stem cells within a tissue could lead to the accumulation of 
mutations, however, stem cells as the origin of cancer has not yet been definitively 
shown. It is important to note, that studies within this field do not directly identify the cell 
of origin within the different cancer types but instead remain a characterization of the 
heterogeneous growth of cancer cells within a particular population. In our studies, we 
do conclude that our identified cancer stem cells possess the properties of self-
renewing and multipotency, however, we do not assert that the ALDHhighCD44high cells 
are derived from an actual salivary gland stem cell. While direct definition and 
categorization of these cells is still elusive, we maintain that overcoming cancer stem 
cell resistance to traditional therapies by targeting self-renewal and differentiation 
pathways remains an important area of study regardless of whether or not the cells are 
truly stem cells. 
Collectively, this work demonstrates that salivary gland mucoepidermoid 
carcinomas exhibit a small sub-population of cells with uniquely high tumorigenic 
potential. These cells can be identified by high ALDH activity and CD44 expression. 
This work also demonstrates that inhibition of p53 and MDM2 binding effectively targets 
ALDHhighCD44high cancer stem cells in salivary gland mucoepidermoid carcinoma 
through activation of p53 and differentiation of the cells into non-cancer stem cells both 
in-vitro and in-vivo. Activation of p53 by inhibition of MDM2 binding also induces cells 
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cycle arrest and apoptosis in mucoepidermoid carcinoma cells in-vitro and in-vivo 
leading to cell death and tumor shrinkage. These results suggests that cancer stem 
cells play an important role in mucoepidermoid carcinoma and that patients with 
mucoepidermoid carcinomas may benefit from MDM2 inhibition therapies that target 
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